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Abstract 
 Lung cancer is the most common cause of cancer death worldwide. Despite the 
increasing knowledge on the mechanisms underlying the tumorigenic process, there isn’t 
a significant increase on lung cancer patients’ survival. Due to this, it is urgent to develop 
new approaches that surpass the chemotherapeutic resistance, both intrinsic as acquired, 
observed with the current available therapeutic options.  
 Tumours are characterized by their cellular heterogeneity due to the co-existence 
of different cellular sub-populations, whose hierarchic organization in certain cancers 
lead to the hypothesis that the target cells of transforming mutations are stem-like cells. 
However, in other tumours, restricted progenitors or even differentiated cells may be the 
cell of origin. Cancer stem cells (CSCs) are consequently, stem-like cells with self-
renewal and multipotent differentiation characteristics which can originate all cell types 
found in a tumour.  
Recently, following prolonged treatment of differentiated non-tumorigenic 
bronchial epithelial cells (BEAS-2B) with hexavalent chormium, a known lung 
carcinogenic agent, a malignant cell line RenG2 was established and, subsequently, two 
more malignant cell lines, DRenG2 and DDRenG2, were implemented out of tumors 
induced in nude mice. Unexpectedly, we demonstrated that CSCs could be obtained by 
dedifferentiation of the malignant bronchial epithelial cells DRenG2, DDRenG2 and/or 
their precursor RenG2. 
 In the present work the proliferation rate of Cont-1, RenG2, DRenG2 and 
DDRenG2 cell lines, and their non-malignant precursor BEAS-2B was assessed by the 
trypan blue method. The cytogenetic evolution from BEAS-2B to DDRenG2 was 
evaluated, and the epithelial/mesenchymal phenotype of the cell lines was assessed by 
immunocytochemistry (MNF116, Vimentin and Oct3/4). Finally, the chemoresistance of 
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the cells lines to gemcitabine (2’2’-diflourodeoxycytidine) and cisplatin [cis-
Pt(NH3)2Cl2], the most common drugs used to treat lung cancer, was evaluated and 
correlated to the presence of the efflux pump P- Glycoprotein. The MTT (3-[4, 5-
dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) assay was used to assess the 
ability of gemcitabine and cisplatin to reduce cells’ viability.  
 The cytogenetic analysis of the more malignant and more proliferative DRenG2 
and DDRenG2 cell lines revealed a common structural difference relative to progenitor 
BEAS-2B cells in chromosome 7 (7p
-
). However, while the predominant structural 
alterations in DRenG2 were the 7q
-
 and iso9q
+
, DDRenG2 revealed the predominance of 
t(7:14) and 17q
+
. All the malignant cell lines, RenG2, DRenG2 and DDRenG2, 
predominant ploidy was 75/76 chromosomes in contrast, to their non-malignant 
progenitor BEAS-2B and non-malignant control Cont-1. 
 Immunocytochemistry analysis revealed that all cell lines were MNF116- and 
Vimentin-positive but, Otc3/4- and P-Glycoprotein-negative. The MNF116- and 
Vimentin staining levels distribution revealed that all the cell lines were composed of 
different cellular sub- populations that account for their transition phenotypes, with 
BEAS-2B more epithelial while the more malignant were more mesenchymal. As 
expected, the more malignant cell lines were significantly more resistant to gemcitabine 
and cisplatin.  Although, quite often multidrug resistance is associated to the 
overexpression of the membrane efflux pump P-Glycoprotein, other mechanism(s) may 
account for the observed resistance of DRenG2 and DDRenG2 cells. 
 
 
Keywords: Lung cancer, resistance to gemcitabine and cisplatin, transition phenotypes 
epithelial and mesenchymal, structural cytogenetic alterations 7q
-
, iso9q
+
, t(7;14) and 
17q
+
, polyploidy and malignancy. 
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Resumo  
 
O cancro do pulmão é a principal causa de morte por cancro a nível mundial. 
Apesar do crescente conhecimento sobre os mecanismos subjacentes ao processo 
tumorigénico não se tem observado alteração significativa na sobrevivência dos 
pacientes. É, por isso, urgente encontrar novas estratégias terapêuticas que visem superar 
a resistência, tanto intrínseca como extrínseca, observada com a quimioterapia corrente. 
Os tumores são caracterizados pela sua heterogeneidade celular, devido à 
coexistência de diferentes subpopulações celulares, cuja organização hierárquica em 
certos tipos de cancro, levou à hipótese de que as células afetadas por mutações possam 
ser células estaminais e estar na origem do processo tumoral. No entanto, em outros 
tumores, células totalmente diferenciadas portadoras de mutações têm sido referenciadas 
como as células de origem. As células estaminais cancerígenas, são células com 
capacidade de autorrenovação, e diferenciação multipotente, que podem originar os 
diferentes tipos de células presentes no tumor.  
Recentemente, a fim de estudar os mecanismos envolvidos na carcinogénese 
pulmonar por exposição ao crómio hexavalente [Cr(VI)] foi implementado, no nosso 
laboratório, o primeiro sistema in vitro de transformação maligna de uma linha do epitélio 
bronquial humano, BEAS-2B, induzida por Cr(VI). Subsequentemente, o potencial 
maligno da linha celular obtida (RenG2) foi aumentado por injecções sucessivas das 
células em ratinhos imunocomprometidos, estabelecendo duas novas linhas celulares 
malignas, derivadas da inicial (DRenG2 e DDRenG2). Inesperadamente, demonstrou-se 
que as células estaminais cancerígenas, podem ser obtidas por desdiferenciação de células 
malignas do epitélio bronquial, e/ou da percursora menos maligna RenG2.  
Tendo em vista a caracterização biológica das linhas celulares: Cont-1, RenG2, 
DRenG2, DDRenG2 e BEAS-2B procedeu-se, ao estudo dos seus tempos de duplicação, 
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pelo método de azul tripano, e da evolução citogenética desde as BEAS-2B até às 
DDRenG2. Após a caracterização citogenética das linhas celulares o fenótipo epitelial, 
mesenquimal das referidas linhas foi avaliado por imunocitoquímica (MNF116, 
Vimentina e Oct-4). Por fim, a resistência aos agentes quimioterapeuticos 
convencionalmente usados no cancro do pulmão, gemcitabina (2’2’ diflouro 
deoxicitidina) e da cisplatina [cis-Pt(NH3)2Cl2], foi avaliada  e correlacionada com a 
expressão da proteína de efluxo P-Glycoproteína. O método do MTT (brometo de 3- [4,5-
dimetiltialzol-2-il] -2,5-difeniltetrazólio) foi utilizado para avaliar a resistência aos 
referidos fármacos. 
A análise citogenética das linhas celulares mais malignas e proliferativas DRenG2 
e DDRenG2 demonstrou que estas eram portadoras de uma alteração estrutural comum 
relativamente à progenitora não maligna BEAS-2B, denominada 7p
-
. As principais 
características citogenéticas da linha DRenG2 eram as alterações estruturais 7q
- 
e da 
iso9q
+
, enquanto as da linha celular DDRenG2 eram as alterações t(7;14) e 17q
+
. As 
linhas celulares malignas RenG2, DRenG2 e DDRenG2 apresentaram uma ploidia de 
75/76 cromossomas em oposição às linhas não malignas BEAS-2B e Cont-1. 
A análise imunocitoquímica revelou que todas as linhas celulares eram MNF116- 
e Vimentina-positivas mas, Otc3/4- e P-Glycoprotein-negativas. Como esperado, as 
linhas mais malignas, apresentaram uma maior resistência à gemcitabina e cisplatina. 
  
Palavras-chave: Cancro pulmonar, resistência à gemcitabina e cisplatina, fenótipos de 
transição epitelial e mesenquimal, alterações citogenéticas 7q
-
, iso9q
+
, t(7;14) e 17q
+
, 
poliploidia. 
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1.1 Cancer epidemiology 
In the last decades, scientists have overcome many difficulties in order to fight the 
diseases that plague our world.  The discovery of new techniques of investigation and the 
improvement of the available technology, allowed many battles to be won, even though 
some diseases remain incurable. Among these diseases is cancer, a worldwide concern 
that affects millions of persons every year. However, the cure of cancer is still unknown.  
Cancer is the leading cause of death in economically developed countries. In 
2008, it was responsible for 7.6 million deaths worldwide. In the past, cancer was known 
to be a disease of the developed countries; nerveless, it already spread into undeveloped 
countries where cases have been documented. Worldwide, the most commonly diagnosed 
cancer is lung cancer (LC) (1.61 million of incidences, corresponding 12.7% of the total) 
followed by breast cancer (1.38 million of incidences, 10.9% of the total) and colorectal 
cancer (1.24 million of incidences, 9.8% of total). Accordingly, LC is also the most 
frequent cause of cancer-related deaths (1.38 million deaths, 18.2% of the total), followed 
by stomach cancer (738 000 deaths, 9.7% of the total) and liver cancer (695 000 deaths, 
9.2% of the total) (Siegel et al., 2011). According to the International Agency for 
Research on Cancer (IARC), the prevalent cancer varies between genders, being LC the 
most frequent among men (949 000 deaths, 22.5% of the total), while is breast cancer is 
the prevalent among women (459 000 deaths, 13.7% of total). In the figure 1.1 is 
represented the incidence (blue) and the mortality (red) of the 15 most frequent types of 
cancer worldwide in 2008.   
                                                                       Chapter 1 – Introduction  
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Figure 1.1 – Comparison of the most frequent cancers among genders. As 
depicted in this graph the main cause of cancer related deaths worldwide is the lung 
cancer in 2008. ASR: age-standardised rates. (http://globocan.iarc.fr/) 
    
1.2 Cancer tissue-specific phenotypes etiology   
The molecular and cellular mechanisms underlying the origin of tumour 
phenotypes remain a central question in the cancer biology field. So far two models have 
been proposed, to explain tissue-specific phenotype heterogeneity. The first model argues 
that different genetic and/or epigenetic mutations occur within the same target cell 
resulting in different tumour phenotypes. On the other hand, the second model states that 
different tumour subtypes arise from distinct cells, which will act, within the tissue, as the 
cell of origin (Figure 1.2) (Visvader, 2011). As these mechanisms are not mutually 
exclusive, they may eventually together to control tumour histopathology and behaviour. 
                                                                       Chapter 1 – Introduction  
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Figure 1.2 – The two models of intertumoural heterogeneity.  A. In the genetic 
(and epigenetic) mutation model, mutations primarily determine the phenotype of the 
tumour, such that different mutations result in different tumours morphologies. B. In 
the cell-of-origin model, different cell populations along the lineage hierarchy serve 
as cells of origin generating different cancer populations within the organ or tissue. 
(Adapted from Visvader, J.E., 2011). 
 
1.3 Malignant transformation etiology   
1.3.1 The hallmarks of cancer  
Cancer cells are characterized by a variety of genomic defects, such as 
inactivation of DNA repair genes, over-expression of growth promoting oncogenes, extra 
or missing chromosomes, abnormal number of centrosomes, aberrant mitosis and 
cytokinesis (Meraldi et al., 2004). In a recent review, Hanahan and Weinberg (2011) 
stated that all cancer cells, in spite of their remarkable diversity, have common features 
including: inability to respond to signals of programmed cell death and unresponsiveness 
to anti-proliferative signals; prevalence in a proliferative state in the absence of mitogenic 
signals; loss of sensors to programmed senescence; sustained angiogenesis, tissue 
invasion and metastasis; reprogramming of energy metabolism and evading immune 
destruction (Figure 1.3).  
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6 
 
 
Figure 1.3 – The hallmarks of cancer (Adapted from Hanahan and Weinberg, 
2011). 
 
It is now accepted that the environment surrounding the cancer cells, designated as 
“tumour microenvironment”, also contributes to tumorigenesis in cancers of epithelial 
origin, as known as, carcinomas (Hanahan and Weinberg, 2011; Hu and Polyak, 2008; 
Littlepage et al., 2005). In fact, contradicting the ancient belief that the recruited normal 
cells, which form tumour-associated stroma, were merely passive bystanders, several 
recent works demonstrated that the tumour microenvironment, contributes largely to 
tumorigenesis, acting as a regulator of the progression to invasion and metastasis 
(Hanahan and Weinberg, 2011; Hu and Polyak, 2008; Littlepage et al., 2005).  
The multiple theories that tried to explain the origin of malignant transformation 
were, almost inevitably, in line with the more general pathological theories at the time 
they were postulated (Triolo, 1965). As a consequence, the establishment of cancer as a 
genetic disease paralleled the development of the discipline of genetics. The designation 
of cancer as “the disease of genes” emerged from the observation that alterations in 
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certain genes drive normal cells to ignore growth-controlling signals, and to the 
emergence of tumour masses that eventually disseminate (Shipitsin and Polyak, 2008). 
The failure in cellular homeostasis control, observed in cancer cells, is commonly related 
with mutations and/or abnormal expression of oncogenes (mutated forms of proto-
oncogenes), tumour suppressor genes (Tp53, Rb, APC and BCRA1), which may be 
triggered by some chromosomal alterations (i.e. translocations) (Argyle and Blacking, 
2007). Proto-oncogenes are important genes that are involved in the control of cell 
growth, proliferation and differentiation. In normal cells, proto-oncogenes can be grouped 
as: growth factors, growth factor receptors, protein kinases, signal transducers, nuclear 
proteins and transcription factors. As to tumour suppressors, they generally operate as 
central branches within complementary cellular regulatory circuits, responsible for cells 
proliferation or, alternatively, for the activation of senescence and/or apoptotic programs.  
To convert a proto-oncogene into an oncogene it is only necessary a single allele 
mutation (punctual mutation, deletion, insertion, gene amplification and chromosomal 
translocation).  Conversely, for the loss of function of a tumour suppressor required to 
initiate the malignant transformation, it is necessary that both alleles are lost. Mutations 
or translocations of these genes can lead to abnormal uncontrolled cell growth, and 
consequently to malignant transformation (Argyle and Blacking, 2007; Yagui-Beltrán and 
Jablons, 2009).  However, new evidence suggests that each tumour suppressor gene 
operates in a larger network, and so, cells lacking a functional Rb or Tp53 gene can 
surprisingly be free of proliferative abnormalities, despite the expectation that loss of 
these genes function would allow continuous abnormal cell division cycle (Hanahan and 
Weinberg, 2011). These cases develop abnormalities only late in life.  
In addition to genetic mutations, it is now well established that epigenetic changes 
that occur manly in the CpG islands can be adjuvants or even surrogates of genetic 
                                                                       Chapter 1 – Introduction  
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mutations. CpG islands are genomic regions that contain a high frequency of CpG sites 
and some CpG dinucleotides clustered in promoter regions (Yagui-Beltrán and Jablons, 
2009). Whenever these regions accomodate genes that are involved in tumour 
suppression, their specific DNA hypermethylation leads to the silencing of these tumour 
suppressor genes (Herman and Baylin, 2003). If a simultaneously hypomethylation occurs 
at the promoter regions of oncogenes, inducing their activation and up-regulation, a 
generalized genomic instability takes place, favouring the malignant transformation 
process not only allows up-regulated transcription of oncogenes but, also, when 
generalized, genomic instability (Eden et al., 2003; Nishigaki et al., 2005). This 
additional level of complexity sheds light on the marked heterogeneity of cellular 
morphology, proliferative index, genetic lesions and therapeutic response of cancer cell 
populations present within the same tumour (Feinberg et al., 2006). 
 
1.3.2 The stochastic model   
Till recently the model proposed for cancer formation was the stochastic or clonal 
evolution model, which argues that cancer establishment, is a long term process, starting 
with a malignant transformation (chemical, physical or biological carcinogenic agent), 
which affects the genome of the cell. Then a clonal expansion takes place which might 
lead to tumour development and propagation, and, eventually, death. According to this 
model, tumour’s heterogeneity is the result of genetic mutations in individual cells, and of 
a paracrine crosstalk between mutated cells and their microenvironment (Figure 1.4) 
(Argyle and Blacking, 2007). 
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Figure 1.4 – The stochastic model of carcinogenesis. Cancer formation is the 
phenotypic consequence of panoply of changes that may have taken a long period of 
time to develop. Following an initiation step, activated by a cancer-inducing agent, a 
period of tumour promotion takes place. Each stage of the multi-step carcinogenic 
process reflects genetic and/or epigenetic changes in the cell, which will provide the 
selective advantage to drive the progression towards a highly malignant state. The 
age-dependent incidence of cancer suggests a requirement of four to seven rate 
limiting, stochastic events to produce the malignant phenotype (Adapted from 
Argyle and Blacking, 2007).     
 
   
 
1.3.3 The hierarchical or stem cell model   
1.3.3.1 Stem cells  
Mammals have three basic cells types in their bodies: germ cells, somatic cells 
and stem cells (SCs). Populations of stem cells with unique properties exist in essentially 
all tissues of a multicelular adult organism (Shipitsin and Polyak, 2008; Ashkenazi et al., 
2008). One of the most important characteristics of SCs is their ability to generate full 
lineages of differentiated cells through a process called differentiation. This provides the 
differentiated cell, with the ability to perform a specific function, i.e., a liver cell, a blood 
cell, or a neuron. This process is very common during the development of a multicelular 
organism since its evolution from a simple zygote till a complex system of tissues and 
different cell types. Moreover, as the long-lived SCs subsist throughout the entire life 
                                                                       Chapter 1 – Introduction  
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span of organisms, they are attractive targets of tumorigenesis, a process that often 
requires years to elapse (Shipitsin and Polyak, 2008; Ashkenazi et al., 2008).  
 
 
Figure 1.5 – Basic outline of stem cell functioning (Adapted from Bapat et al., 
2009). 
 
SCs are mainly characterized by their ability to go through numerous cycles of 
cellular division while maintaining the undifferentiated state (self-renewal), and their 
capacity to differentiate into specialized cell types (potency). Another important property 
of SCs is their homeostatic control, i.e., the existence of tight mechanisms regulating the 
balance between self-renewal/differentiation and quiescence/proliferation, in all tissues 
and organs. This mechanism is largely influenced by environmental stimuli and genetic 
constrains in order to maintain stem cell numbers (self-renewal capability) via the ratio of 
symmetric and asymmetric cell divisions (Bapat et al., 2009).  
In asymmetric cell divisions, each stem cell divides to generate one daughter stem 
cell, that has the same properties as the parent cell (self-renewal), and one daughter cell 
intended to differentiate (Figure 1.6A). Conversely, in symmetric cell divisions, each SC 
can generate two phenotypically identical daughter cells that can be either stem cells 
(symmetric self-renewal) or differentiated cells (symmetric differentiation) (Figure 1.6B) 
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(Ashkenazi et al., 2008; Morrison and Kimble, 2006). SCs division can be either 
controlled by the stem cell itself (intrinsic) or by paracrine factors produced at the SC 
niches by stromal cells (extrinsic) (Miller et al., 2005).   
 
A. Asymmetric division  
 
 
 
B. Symmetric division 
 
 
Figure 1.6 – Stem cell division models. Asymmetric self-division (A), results in one 
stem cell and one pluripotent cell. Symmetric division (B) can comprise symmetric 
self-renewal and symmetric differentiation which results in two daughter stem cells 
or two progenitor cells, respectively.    
 
 
 SC niches regulate the contribution of stem cells to tissue development, 
maintenance and repair (Scadden, 2006). Those niches integrate signals elicited by the 
surrounding environment which mediates the response of stem cells to the needs of the 
organisms. Therefore, dysfunctional signals from the environment play an important role 
on the onset of diverse pathologies, including cancer. Another important function of the 
SC niches is to avoid the depletion of stem cells, while protecting the host tissue from SC 
uncontrolled proliferation. 
 
 
 
Stem cell 
Differentiated 
cell 
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1.3.3.2 Cancer stem cells: What is known about?  
According to the stochastic model, the malignant transformation is understood as 
a disruption of homeostasis during which normal cells suffer multiple genetic mutations, 
which will provide all cells with higher proliferative capacity (Figure 1.7a) (Reya et al., 
2001; Argyle, and Blacking, 2007; Miller et al., 2005).  
 
 
Figure 1.7 – Two general models of heterogeneity in solid cancer cells. a, Cancer 
cells of many different phenotypes have the potential to proliferate extensively. The 
model shown in b predicts that a distinct subset of cells is enriched for the ability to 
form new tumours, whereas most cells are depleted of this ability (Adapted from 
Reya et al., 2001).   
 
However, this model is unable to explain the clinical remissions and relapses of 
many tumours observed following chemo- and radio therapies. Additionally, the 
recognition that tumours are highly heterogeneous entities, composed of multiple cellular 
sub-populations with a wide range of malignant, tumorigenic and metastatic potentials, 
led to the proposal of the hierarchical or the SC model. According to this model, the stem 
cells or cells that acquired the SCs properties, accumulate genetic changes over long 
periods of time, escaping from the control of their environment, originating cellular sub-
populations with dissimilar malignant, tumorigenic and metastatic potentials (Figure 1.7b 
and 1.8) (Reya et al., 2001; Shipitsin and Polyak, 2008; Visvader, 2011). These cells, 
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called cancer stem cells (CSCs), due to their stem cell-like characteristics, such as, the 
capacity for asymmetric divisions, giving birth to a quiescent stem cell and a committed 
progenitor cell; expression of stem cell characteristic factors such as Oct4, Nanog, and 
Sox2; expression of adenosine triphosphate (ATP)-binding cassette (ABC) transporters, 
contributing to cellular resistance to specific cytotoxic and cytostatic drugs; extended 
telomeres and telomerase activity and, consequently, increased cellular life span; 
resistance to apoptosis as result of antiapoptotic pathways activation; and, finally, 
expression of surface receptors either identical to the stem cell markers or associated with 
homing and metastasis (Wicha et al., 2006; Bapat et al., 2009),  have been proposed to 
start off either from malignant transformation of a normal somatic cell or a progenitor cell 
and, in the tumour, are credited as the only cells with tumorigenic and metastatic potential 
(Welte et al., 2010). 
 
 
Figure 1.8– The cell of origin and the evolution of a cancer stem cell. Cellular 
hierarchy starting off with stem cells progressively, generating common and more 
restricted progenitor cells to, finally, yield all the mature cell types that constitute a 
specific tissue. Although the cell of origin, for a particular tumour, could be an early 
precursor cell such as a common progenitor, the subsequent acquisition of further 
genetic/epigenetic mutations by a cell, within the aberrant expanding population 
during neoplastic progression, may result in the emergence of a CSC. According to 
this model, only the CSCs (and not other tumour cells) are capable of sustaining 
tumorigenesis. Thus, the cell of origin, that initiates tumorigenesis, may be distinct 
from the CSC which propagates the tumour. (Adapted from Visvader, 2011).   
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Because normal SCs and CSCs share the ability to self-renew, it seems reasonable 
to propose that newly arising CSCs appropriate the machinery for self-renewing cell 
division that is normally expressed in normal SCs. Evidence shows that many pathways 
that are classically associated with cancer may also regulate normal SC development, for 
example, the prevention of apoptosis, by enforced expression of the oncogene Bcl-2, 
results in increased numbers of SCs in vivo, suggesting that cell death has a role in 
regulating their homeostasis (Domen et al., 1988; Domen and Weissman,  2000). Other 
signalling pathways associated with oncogenesis, such as the Notch, Sonic Hedgehog 
(Shh) and Wnt signalling pathways, also regulate stem cell self-renewal (Reya et al., 
2001; Hanahan and Weinberg, 2011).Notch activation in hematopoietic stem cells (HSCs) 
in culture using the ligand Jagged-1 have consistently increased the amount of primitive 
progenitor activity that can be observed in vitro and in vivo, suggesting that Notch 
activation promotes HSC self-renewal, or at least the maintenance of their 
multipotentiality (Varnum-Finney et al., 2000; Karanu et al., 2000). 
CSCs, first identified in the hematopoietic system because of their unique 
properties have also been termed “tumour-initiating cells even though the cell of origin in 
which tumorigenesis is initiated may be distinct from the CSC, which propagates the 
tumour (Visvader, 2011). Although the origin of CSCs is rather controversial, several 
authors considered that CSCs are engendered by differentiation of malignant stem or 
progenitor stem-like cells and, as such, are sometimes represented as an intermediate state 
between malignant stem cells and malignant differentiated cells (Welte et al., 2010) 
(Figure 1.9). However, very recently, our group (Rodrigues et al., 2011) and Weinberg 
and collaborators (Chaffer et al., 2011) attested that CSCs may also arise by 
dedifferentatiation of malignant epithelial cells. 
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Figure 1.9 - Relationship between stem cells and their differentiation states. 
Stem cells are characterized by their ability to differentiate into different cellular 
phenotypes, originating many different types of tissues, and by their capacity to self-
renew. In contrast to progenitor SCs, differentiated cell has reduced plasticity.  
According to some authors’, cancer stem cells may arise at the interface between 
stem cells and progenitor cells (Adapted from Welte et al., 2010). 
 
 
 
More recently, the presence of sub-populations of CSCs in tumours of lung, 
prostate, brain, colon and in malignant cell lines from different origins have been 
identified by their cell surface markers, which are important biomarkers, ideal for their 
isolation by flow cytometry. The following Table 1 illustrates a wide range of CSCs 
characteristic biomarkers.  
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Table I – Characteristic CSCs biomarkers used to isolate CSCs from various 
malignancies (Adapted from Boman and Wicha, 2008). 
 
 CD133, the structural homolog of murine prominin-110, is regarded as an 
important marker for the identification and isolation of primitive stem and progenitor 
cells, present in a variety of cancers (Boman and Wicha, 2008). The CD133 positive 
(CD133
+
) cells, ascribed as CSCs, are provided with tumour-initiating capacity in 
contrast with their CD133
- 
counterparts (O’ Brien et al., 2009). CD44 is another important 
biomarker reported as characterizing CSCs in breast, colon, prostate, head and neck, 
pancreatic, melanoma and leukaemia tumours. Interestingly, the presence of cells with 
profile CD44
+
/CD24
-/low
, which outlines the presence of CD44 and the absence of CD24 
expression markers, identifies breast-tumour initiating cells (Al-Hajj and Clarke, 2004). 
Another important CSCs biomarkers not included in Table 1, is CD34 a sialomucin 
protein used to identify hematopoietic stem/ progenitor cells in clinical hematology. The 
profile CD34
+
/CD38
-
 identifies CSCs subpopulations present in acute myeloid leukemia 
(AML) (Ailles and Weissman, 2007).  
Another approach used to identify CSCs is the side population (SP) assay. This 
assay exploits the capacity of CSCs to efflux certain drugs and dyes, such as Hoechst 
33342 (Wu et al., 2012). Exclusion of Hoechst 33342 dye by SP cells is a dynamic 
process involving the multidrug resistance transporter 1 (MDR1), a member of the ABC 
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transporter transmembrane proteins, named P-glycoprotein (P-gp).  As CSCs express high 
levels of cell membrane ABC transporter proteins, they are provided with the ability to 
efflux chemotherapeutic drugs (O’ Brien et al., 2009; Tang et al., 2007). Therefore, it is 
expected that cells with tumour-initiating capacity exist exclusively within the SP
+
 
population. Schatton and collaborators revealed that ABCB5
+
 SP melanoma cells 
expressing the 5
th
 ABC, from the subfamily B, are tumour-initiating cells in contrast with 
their ABCB5
-
 counterparts (Schatton et al., 2009).  
Despite the latest improvements in CSCs identification, investigation should 
continue in order to achieve a better understanding of the role of CSCs in tumours 
formation and proliferation.   
 
1.3.3.3 CSCs and resistance to chemotherapy 
Multi-drug resistance (MDR) is classically defined as a state of resilience against 
structurally and/or functionally unrelated drugs. This resistance can be inherent (intrinsic) 
to the cells or acquired after exposure to chemotherapeutic agents (Milane et al., 2011). 
Existing therapeutic approaches have been designed largely based on the stochastic 
model, since most chemotherapeutic agents are addressed to the tumour major sub-
populations which have limited self-renewal and proliferative potential. As most 
therapeutic effects are usually transient and fail to ablate most cancers, future therapies 
based on the hierarchical model are thought to be much more successful. In fact, as 
referred above, CSCs have the ability to self-renew and to generate a wide range of 
cellular sub-populations within the tumour, and are responsible for sustaining 
tumorigenesis. So, a successful cancer therapy would necessarily have to abrogate the 
CSCs population (Figure 1.10). However, so far such therapy has not been developed, 
mainly because CSCs are highly radio- and chemo-resistant and, as such, the dose of 
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either chemo- or radio agent necessary to eliminate the CSC population would kill the 
patient. This way, while a targeted therapy is being designed, tumours often relapse after 
conventional treatments, and patients often die of metastatic disease (Reya et al., 2001; 
Schatton et al., 2009).  
 
 
Figure 1.10 – Effective cancer therapy may require combination treatments, A. 
An effective therapy would be the combination of the drug X, targeting the bulk 
tumour cells that are well-differentiated and the drug Y, which kill cells with a CSC 
phenotype. Cancer cells treated with drug X may undergo EMT, in order to acquire 
CSC-like properties, in which case co-administration of drug Y would kill both pre-
existing CSCs and those that emerge via treatment with Drug X. B. A novel strategy 
to eliminate CSCs could be to induce their differentiation, which may lead to 
intrinsic apoptotic cell death, or may sensitize the resulting differentiated cells to 
existing therapies (Adapted from Singh and Settleman, J., 2010).   
 
CSCs resistance to chemotherapy relies on several mechanisms, the most 
important of which are the increased DNA damage recognition and repair, the alterations 
of cell cycle checkpoints the impairment of tumour apoptotic pathways the reduced 
accumulation of cytotoxic chemotherapeutic agents, through enhanced energy-dependent 
drug efflux and the increased Wnt/β-Catenin and Notch proliferating signalling pathways 
(Milane et al., 2011; Eyler and Rich, 2008).  
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It seems that a good strategy to prevent the resistance to chemotherapy and, 
consequently, to eliminate tumour cells relies on the inhibition of the main drug 
transporters (Dean et al., 2005). Alternatively, treatments that target CSCs specific 
markers or signalling pathways critically involved in CSCs function seem also to reduce 
the risk of relapse and dissemination. However, given the similarities between CSCs and 
normal SCs, the development of CSC-directed treatment strategies will have to be 
carefully implemented. Moreover, as CSCs represent a heterogeneous cell population 
with rather different resistance profiles, several therapeutic agents will have to be used 
(Singh and Settleman, 2010). 
 Due to what was mentioned before, a novel strategy to eliminate CSCs could be 
to induce their differentiation, which could lead to intrinsic apoptotic cell death or could 
sensitize the resulting differentiated cells to existing therapies (Singh and Settleman, 
2010). 
Recent advances in cancer genomes indicate a role for epigenetic regulators in 
driving cancer, which may result in the acquisition of additional (epi)genetic 
modifications (changes in gene expression that are independent of changes in DNA 
sequence and persist over many cell divisions, leading to drug resistance (Wilting and 
Dannenberg , 2012). These observations may lead to the development of new anticancer 
drugs, called epigenetic drugs that can prevent or reverse non-responsiveness to anti-
cancer drugs.  
Besides the epigenetic changes mentioned before, recent data showed, that drug 
resistance mechanisms might also be regulated by microRNAs (miRNAs) (Giovanetti et 
al., 2011). miRNAs are small, non-coding and evolutionary conserved RNA molecules, 
and are negative regulators of gene expression through modulation of the post-
transcriptional activity of multiple target mRNAs by direct cleavage or repression of 
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translation, so their up- and/or down-regulation influence the expression of multiple target 
mRNA, and consequently multiple proteins, leading to variations in chemosensitivity of 
cancer cells (Wang et al., 2010).  
 
 
1.3.4 Cellular plasticity 
A typical epithelium is a layer of cells, often one cell thick, lying on the top of 
connective tissue. The epithelium, separated by a basement membrane from the 
connective tissue, has cell-cell junctions and adhesions that hold tightly the neighbouring 
epithelial cells and inhibit the movement of individual cells away from the monolayer, 
thus imposing mechanical rigidity. This rigidity and the lateral migration prevent the 
epithelial cells to enter into the underlying extracellular matrix (ECM), unlike 
mesenchymal cells which can traverse individually the ECM (Yang and Weinberg, 2008; 
Zavadil and Bottinger, 2005). The ECM, formed by an interstitial matrix and a basement 
membrane where epithelial cells rest, provides structural support to the animal cells, 
separating tissues from one another, and regulates intercellular communication.  
An important characteristic of epithelial cells is their polarity, denoting that the 
apical and basal surfaces are likely to be visually differently, have different functions and 
adhere to different molecules (Figure 1.11). In contrast, the end-to-end polarity and the 
absence of tight intracellular adhesions, provide the more extended and elongated 
mesenchymal cells with prominent migratory capacity. The migratory features of 
epithelial and mesenchymal cells are also somewhat different, with epithelial cells 
moving as a sheet “en block”, while the mesenchymal cells are rather more dynamic 
(Figure 1.11) (Lee et al., 2006). Different sets of proteins used as biomarkers, allow the 
distinction between these two cell types (Tiwari et al., 2012) (Figure 1.11).  
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The transmembrane proteins cadherins play important roles in cell adhesion, 
ensuring that cells within tissues are bound together. The presence of E-cadherin, in 
epithelial cells, is essential for the great cell-cell adhesion strength observed in epithelium 
when compared with to the N-cadherin-expressing mesenchymal cells (Lee et al., 2006). 
The integrins, which are heterodimeric transmembrane proteins formed by α and β 
subunits, are other important players in cell adhesion. These receptors mediate the 
attachment between a cell and the surrounding tissues, which may be other cells or the 
ECM. During the process of tumour cell invasion, integrins, which bind to various ECM 
components, critically regulate cell adhesion to the basement membrane (Maschler et al., 
2005). Additionally, integrins play an important role in cell signalling, thereby regulating 
the cellular shape, motility, and cell cycle.  
 
 
Figure 1.11 – The epithelial and mesenchymal cell biomarkers used to 
differentiate epithelial from mesenchymal cells. The epithelial to mesenchymal 
transition (EMT) encompasses the functional transition of polarized epithelial cells 
into the ECM component-secreting, mobile mesenchymal cells. Detection of cells 
expressing both sets of markers renders impossible to identify whether it is an 
epithelial cell or a mesenchymal cell. Fortunately, all mesenchymal cells are devised 
from the epithelia via EMT, as many mesenchymal cells likely lose all epithelial 
markers once a transition is completed (Adapted from Kalluri and Weinberg, 
2009). 
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Epithelial-to-mesenchymal transition (EMT) and the reverse process known as 
mesenchymal-epithelial transition (MET), occur widely during embryonic development 
and represent clear examples of what is called cells’ phenotypic plasticity (Thiery, 2002; 
Alison et al., 2006; Yang and Weinberg, 2008). The MET process involves the 
conversion of mesenchymal cells to epithelial ones, and is associated with kidney 
formation. On the other hand the EMT process can be defined as a biologic process that 
allows a polarized epithelial cell, to undergo multiple biochemical changes that enable it 
to assume a mesenchymal phenotype (Kalluri and Weinberg, 2009). In other words, the 
EMT is responsible for the generation of cells with a distinct phenotype capable of 
allowing the invasion of the local surrounding tissues, and eventually, the systemic 
dissemination. (Figure 1.11) (Kalluri, 2009). The ability to migrate and invade ECM as 
single cells is a functional hallmark of the EMT program (Yang and Weinberg, 2008). In 
many carcinomas, several EMT-inducing released signals, e.g., hepatocyte growth factor 
(HGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and 
transforming factor beta (TGF-β), appear to be essential for the induction and functional 
activation of a series of transcription factors, especially Snail, Twist, Goosecoid and 
Foxc2 (Thiery, 2002; Kalluri, 2009). In situations of tissue repair and pathological 
stresses, the activation of EMT programs can, also, be assisted by the disruption of cell-
cell adherens junctions and cell-ECM adhesions mediated by integrins, leading to a state 
of cell motility (Kalluri and Weinberg, 2009).  
Several distinct molecular processes are involved along the EMT process, from its 
beginning to its completion, namely for the activation of transcription factors the 
expression of specific cell-surface proteins the reorganization and expression of 
citoskeletal proteins (e.g., CD133 in lung epithelial cells) the production of ECM-
degrading enzymes and the induction of changes on the expression of specific miRNAs 
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and TGF-β (Kalluri et al., 2009; Lee et al., 2006; Mani et al., 2008; Tomaskovic-Crook et 
al., 2009). Among these molecular processes, the changes on the expression of specific 
miRNAs and of TGF-β have been described to directly affect other events that occur 
during the EMT.  
Studies mentioned that EMT involves the downregulation of microRNAs, 
encoding epithelial markers such as E-Cadherin, and the upregulation of microRNAs, 
encoding mesenchymal markers such as N-Cadherin, Vimentin, and Fibronectin (Lee et 
al., 2006; Mani et al., 2008). Thus, changes on cadherin-based adhesion play a key role in 
modulating development and organogenesis, as the activation of EMT program is high 
facilitated by the disruption of cell-cell adherent junctions and cell-extracellular matrix 
adhesions mediated by integrins (Lee et al., 2006; Mani et al., 2008).  Recent discoveries 
revealed that malignant cells lacking E-Cadherin become more responsive to the 
induction of EMT, by various growth factors, and showed an increased tumorigenic and 
metastatic potential when these cells are injected into immunodeficient mice (Kalluri and 
Weinberg, 2009). Also, mutations in the E-Cadherin gene revealed to render malignant 
cells more susceptible to EMT and, consequently, with an increased metastatic potential 
(Kalluri and Weinberg, 2009). 
TGF-β is simultaneously an important suppressor of epithelial cell proliferation, 
and a positive regulator of tumour progression and metastasis, depending on the sub-
pathways activated by this growth factor (Zavadil and Bottinger, 2005). There are also 
some evidences of a relationship between the molecular processes that control TGF-β-
induced apoptosis and those that regulate EMT, as once the cell adopted a mesenchymal 
phenotype it no longer respond to TGF-β suppressor effects (Sánchez and Fabregat, 
2010).  As far as to the involvement of TGF-β family members in the EMT program, 
studies revealed that they play important roles in the initiation and maintenance of the 
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EMT in a variety of biological systems and pathophysiological situations, through the 
activation of major signalling pathways and transcriptional regulators integrated in 
extensive signalling (Sánchez and Fabregat, 2010).   
Another process related with EMT is the dedifferentiation. This is a mechanism 
that requires a differentiated cell to revert to a more primitive stem cell phenotype, in 
other words, the phenotype of specialized cells can be changed, rendering them closer to 
their ancestors with augmented plasticity (Zhang et al., 2010). And, as mentioned before, 
this process can be responsible for the origin of CSCs in humans (Rangwala et al., 2010; 
Ben-Porath et al., 2008). This cellular process can also be seen in more basal life forms 
such as worms and amphibians, which have regenerative process (Stocum, 2004; Casimir, 
1988). 
 
 
1.4 Major cancer histological types   
There is great diversity of histological cancer types, classified based on the 
function and localization of cells of origin. This way there are the carcinomas, tumours of 
epithelial cells, sarcomas that arise from bone, muscle, cartilage, and adipose tissue, and 
the leukemias, lymphomas and myelomas, tumours originated from the hematopoietic 
lineage. The most common histological type is the carcinoma, most likely because of the 
great proliferation competence of the epithelial tissue, and the easy exposure access to a 
wide range of chemical, physical and biological carcinogenic agents.  
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1.4.1 The bronchial epithelium 
The pulmonary system contains a variety of epithelial cell populations residing in 
distinct anatomical locations. Basal, secretory, and ciliated cells are present in the trachea 
and the proximal conducting airways. The nonciliated, columnar Clara cells comprise the 
majority of the bronchiolar and terminal bronchiolar epithelium in mice, and alveolar type 
1 (AT1) and type 2 (AT2) cells constitute the alveolar epithelium (Figure 1.12). The 
conducting airways are constituted by a specialized epithelium whose composition and 
function varies along the proximal to distal axis (Hong et al., 2004). The airway 
epithelium is pseudostratified in the large airways, becoming columnar and cuboidal in 
the small airways (Figure 1.12) (Crystal et al., 2008; Bannister, 1999).  
 
Figure 1.12 – Major cell types of the lung epithelium. In the large airways the 
major cell types are ciliated, undifferentiated columnar, secretory, and basal cells. In 
the small airways, the cell types are similar, with relatively more ciliated cells, and 
the secretory cells shift to the Clara cell type. In the alveoli, the airway epithelium 
merges with the alveolar epithelium, with type I and type II cells (Adapted from 
Crystal et al., 2008).     
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The main role of the airway epithelium is to drive the flux of air to and from the 
alveoli. Another important role is to protect the lung against pathogens and particulates 
inhaled from the atmosphere, which is achieved with the combined function of secretory 
and ciliated cells to sustain an efficient mucociliary clearance.   
The airway epithelium is a dynamic tissue with a slow, but constant renewal, that 
when injured, responds quickly and effectively re-establish the normal structure and 
function of the epithelial layer. Strong evidence supports that stem/progenitor cells 
distributed throughout the airway epithelium are the source of the new epithelial cells, in 
other words, the mature cells of the tissue are constantly replenished by a minority 
population of tissue SCs (Al-Hajj and Clarke, 2004). However the process through which 
this replenishment occurs is still unclear. Recent murine models postulated that during 
normal tissue homeostasis, facultative progenitor cells (Clara cells and Type II 
pneumocytes), situated throughout the lung epithelium, mediate any necessary 
maintenance, due to their capacity to self-renew and differentiate into other lung 
epithelial cell types. However, progenitor cells have a restricted potential to regenerate 
epithelial cells, because they only can regenerate within their resident anatomical 
compartment. So, basal, Clara, or vCE (variant Clara cell secretory protein-expressing 
cells) cells only regenerate the airways while the Type II pneumocytes regenerate the 
alveoli (Delgado et al., 2011). While the maintenance of the adult murine lung is widely 
elucidated, many details concerning the maintenance of human lung remain uncertain 
because it is not possible to transpose the findings directly into humans.   
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1.4.2 Lung cancer 
As mentioned before, LC is the most commonly diagnosed cancer worldwide and 
also the most frequent cause of cancer related deaths (Siegel et al., 2011). The high 
mortality rate of LC is due to the late diagnosis when the only viable options for treatment 
are most palliative (Wistuba and Gazdar, 2006). 
Commonly, LC has an epithelial origin and, as a consequence, is classified as 
carcinoma (Panno, 2005). Lung carcinomas normally arise in the epithelium of the major 
bronchi (central tumours) or in small bronchi, bronchioles, or alveoli (peripheral tumours) 
of the distant airway of the lung. Peripheral tumours usually metastasize widely to lymph 
nodes in the liver, bone and adrenal glands (Wistuba and Gazdar, 2006; Ross, 1998). 
Lung carcinomas are generally divided into two major types: small cell lung 
cancer (SCLC), a highly aggressive and frequently lethal human tumour, which accounts 
for nearly 25% of all lung tumours, and non-small cell lung cancer (NSCLC), that 
accounts for about 75% of the total lung cancers (Risch and Plass, 2008). NSCLC can 
additionally be sub-divided in three major histological types:  squamous cell lung 
carcinoma (SCC), adenocarcinoma (including the non-invasive type of 
bronchioloalveolar carcinoma) and large-cell lung carcinoma (LCC) (Travis, 2011). 
 The SCLC exhibits a more aggressive biological behaviour, disseminating widely 
and being seldom cured by surgical resection. SCLC recurrence after chemotherapy is 
highly frequent. NSCLC may be cured by surgery if diagnosed at early stages but the 
clinical outcome is often hard to determine (Travis, 2011). In addition, SCLC tumours 
have a better initial response to cytotoxic therapies than do NSCLC  
The most common cause of lung cancer is long-term exposure to tobacco smoke. 
Other risk factors which include exposure to nickel, arsenic, chromium and polycyclic 
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hydrocarbons have been accepted as major causes of lung cancer (Coppé et al., 2008; 
Salnikow and Zhitkovich, 2008; Urbano et al., 2008).  
Many substances present in tobacco and other environmental carcinogens induce 
mutation in important genes (e.g., in Tp53 gene), with significant impact in lung cancer, 
as they play important roles in tumorigenesis of lung epithelial cells, and/or disruption of 
some important signalling pathways (Wnt, Hedgehog (Hh),  and Notch) (Toyooka et al., 
2003; Lemjabbar-Aloui et al., 2006; Muller et al., 2007). For example, restricted 
deregulation of Hh signalling, in small patches of epithelial cells, lead to the formation of 
SCLC and, consequently, to tumour maintenance (Magliano and Hebrock, 2003; Watkins 
et al., 2003). Another feature of these pathways is that they are intimately interconnected 
with each other (Katoh, M., et al., 2007).  
Hh, Wnt and Notch are also accountable for triggering a small number of 
signalling pathways that ensure CSCs fate (Magliano and Hebrock, 2003; Reya and 
Clevers, 2005). Therefore, a promising and more specific anticancer therapy is addressed 
to Hh, Notch and Wnt pathways (Muller et al., 2007).     
Besides the signalling pathways mentioned before other key genetic features that 
are commonly associated with lung adenocarcinomas, are the activation of the oncogene 
KRAS, the inactivation of the tumour suppressor genes Tp53, Rb1 and PTEN, the loss of 
heterozygosity (LOH) at selected chromosomal arms, the activation of telomerase and the 
amplification/over-expression of Myc, Cyclin D1, epidermal growth factor receptor 
(EGFR), C-erbB2 and Bcl2 (Licchesi et al., 2008; Risch and Plass, 2008; Pleasance et al., 
2010). The over-expression of EGFR, a receptor tyrosine kinase, of the erbB family is 
one of the most important events in lung cancer. This receptor dimerizes following 
binding to several specific ligands and phosphorylates several tyrosine residues (Arteaga, 
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2002). This event initiates multiple signalling pathways resulting in cells’ proliferation, 
evasion from apoptosis and migration (Kosaka et al., 2004).  
The first targeted therapy to be registered and later approved by the Food and 
Drug Administration (FDA) for use in LC was Gefitinib (Molina et al., 2008; Maemondo 
et al., 2010), a tyrosine cynase inhibitor (TKI), however its activity is limited to a 
subgroup of patients with NSCLC (Lynch et al., 2004; Molina et al., 2008).   
Epigenetic alterations have also been reported to contribute to the initiation and 
progression of several types of cancer, especially adenocarcinomas (Brock, 2008). The 
most common epigenetic event which affects the chromatin condensation status is gene 
silencing by methylation of its promoter at the CpG islands (Risch and Plass, 2008). And 
it was observed that patients with several hypermethylated genes were the most likely to 
develop lung adenocarcinoma (Brock, 2008). 
 
1.4.2.1 CSCs in lung cancer  
As mentioned in section 1.3.3.2 CSCs are present in a wide range of cancers 
including LC (Kim et al., 2005). Besides that, human lung tumours show a phenotypic 
heterogeneity, suggesting that they may originate from a multipotent cell (Berns, 2005). 
Other evidences include the presence, in LC, of sub-populations of SP cells (Ho et al., 
2007), resistant to multiple chemotherapeutic agents such as cisplatin, gemcitabine, and 
vinorelbine, commonly used as first-line therapy in lung cancer treatment (Ho et al., 
2007). Recently, a study revealed the presence, in LC, of a sub-population of cells with 
CD133
+
 phenotype able to self-renew and generate an unlimited progeny of non-
tumorigenic cells, as well as resistant to conventional therapy (Eramo, A., 2008). These 
cells were ascribed to the expression of Oct-4 gene (Chen et al., 2008), an important 
marker for the subset population of cancer stem-like cells.  
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Since CSCs are responsible for the drug resistance observed in many types of 
cancer, including LC, it is of extreme importance to know the molecular and cellular 
mechanisms behind their formation and maintenance, in order to develop more efficient 
cancer-therapies.   
 
 
1.5. Objectives 
The objectives of this work is to evaluate the proliferation rate of Cont-1, RenG2, 
DRenG2 and DDRenG2 cell lines, and their precursor cell line BEAS-2B, the assessment 
of the cytogenetic evolution from BEAS-2B to DDRenG2, the immunocytochemistry 
characterization of these cells by assessing their epithelial/ mesenchymal status [MNF 
116 and Vimentin expression], the presence of stem-like cells (Oct-4 expression) and the 
presence of a member of the ABC transporter transmembrane protein (P-glycoprotein 
expression), and finally, evaluate their resistance to gemcitabine (GEM) and cisplatin 
(cDDP), which are chemotherapeutic drugs usually used in LC.  
 
  
 
  
 
 
 
 
2. Material and Methods 
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All reagents used were of analytic grade. Ultrapure water was obtained using the 
water purification system Simplicity
TM
 from Millipore S.A., Molsheim, France. 
 
2.1    Materials 
Purchased to Sigma-Aldrich Química S.A., Sintra, Portugal: 
 Salts for Phosphate Buffer Solution (PBS) preparation, namely KCl, NaCl, KH2PO4 
and Na2HPO4; 
 NaOH used for the preparation of the pH adjustment solution; 
 Trypan Blue 0,4 % solution (m/v) in PBS, used in cell counting; 
 Dimethyl sulphoxide (DMSO) used for cell culture cryopreservation; 
 2 % Gelatin from bovine skin used to prepare the coating solution; 
 Bovine serum albumin for 1 % gelatin solution preparation; 
 Immersion oil used for microscopy;   
 3-[4, 5-dimethylthiazol-2-yl]2, 5-diphenyltetrazolium bromide (MTT); 
 Formamide used for slide denaturation in fluorescent in situ hybridization. 
 
Purchased to Gibco® Biochrom, CA, USA, through Alfagene, Lisbon, Portugal: 
 TrypLE Express 0,25 % trypsin solution to detach cells; 
 Fetal bovine serum (FBS), used in fibroblasts primary cell culture; 
 Dulbecco’s Modified Eagle Medium (DMEM) and Ham’s F12 cell culture medium, 
used in fibroblasts primary cell cultures; 
 LHC-9 cell culture medium used for epithelial cells cultures;  
 Penicillin and streptomycin used in the preparation of cell culture medium; 
 Colcemide used to stop the cell cycle at pro-metaphase;  
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 Hank’s balanced salt solution (HBSS), used in cell manipulation for cytogenetic 
studies. 
 
Purchased to Panreac Química S.A., Barcelona, Spain: 
 HCl used for the preparation of the pH adjustment solution; 
 Absolute ethanol used for cell fixation protocol during the immunocytochemistry 
analysis and for fluorescent in situ hybridization. 
 
 Purchased to Merk, Darmstadt, Germany, through VWR International, Lisbon, 
Portugal: 
 Methanol used into the preparations of fixation solution for cytogenetic studies; 
 Acetic acid also used in the fixation solution for cytogenetic studies; 
 Giemsa used to stain the chromosomes, which enhances the banding pattern; 
 Gürr buffer at pH 6.8, which was used to prepare the Giemsa solution, and also, to 
wash the slides;  
  KCl, used in the swelling of cells and their nucleus;  
 KH2PO4 used in the solution A of the phosphate buffer pH 6.8, used in the 
cytogenetic analysis;   
 Na2PO4 used in the solution B of the phosphate buffer pH 6.8, used in the cytogenetic 
analysis;  
 NaCl for the preparation of solution 20x SSC used in fluorescent in situ 
hybridization; 
  Sodium citrate for the preparation of solution 20x SSC used in fluorescent in situ 
hybridization; 
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 Tween 20 used in the preparation of the detergent wash solution used fluorescent in 
situ hybridization. 
 
Purchased to European Collection of Cell Cultures (ECACC): 
 BEAS-2B cell line as a cryopreserved cellular suspension. 
 
Purchased to Orange Scientific, Braine-l’Alleud, Belgium, through Frilabo, Porto, 
Portugal: 
 15 and 50 mL centrifuge tubes. 
 
Purchased to Corning Incorporated, NY, EUA, through Sigma-Aldrich Química 
S.A., Sintra, Portugal: 
 12-wells tissue culture plates, used for cell culture; 
 T25 and T75 tissue culture flasks with vent cap, used for cell culture; 
 Petri dishes with diverse diameters.   
 
Purchased to Lab Vision Corporation, Fremont, CA, USA:  
 UltraVision Large Volume Detection System Anti-Polyvalent, HRP (Ready-To-Use) 
Kit, for cell immunocytochemistry analysis; 
 Biotin-labeled secondary antibody used to detect the primary antibody in 
immunocytochemistry analysis; 
 Peroxidase-conjugated streptavidin for localizing the primary antibody binding in 
immunocytochemistry analysis; 
 PBS used to wash the antibodies in immunocytochemistry analysis. 
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Purchased from Difco, MC, USA, through VWR International, Lisbon, Portugal: 
 Trypsin, used in G-banding. 
 
Purchased to DakoCytomation, Glostrup, Denmark,  
 Monoclonal mouse anti-human Cytokeratin antibody, clone MNF116, used for cell 
immunocytochemistry analysis; 
 Monoclonal mouse anti-human Vimentin, clone Vim 3B4, used for cell 
immunocytochemistry analysis. 
 
Purchased from Novocastra Laboratories Ltd, NewCastle, UK: 
 Monoclonal mouse anti-human P-glycoprotein, clone 5B12, used for cell 
immunocytochemistry analysis; 
 3,3-diaminobenzidine tetrahydrochloride (DAB), used to detect the primary antibody 
binding in immunocytochemistry analysis;  
 Monoclonal mouse anti-human Oct3/4, clone N1NK, used for cell 
immunocytochemistry analysis. 
 
Purchased to Hanna Instruments, Woonsocket, USA, through Hanna Instruments 
Portugal, Póvoa do Varzim, Portugal: 
 pH meter calibration solutions.  
 
Purchased to Cambio Lda., Cambridge, UK: 
 Probes used in fluorescent in situ hybridization. 
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Purchased to Sarstedt Lda., Rio Mouro, Portugal: 
 6 and 24-well tissue culture plates, used for cell culture; 
 Cryogenic vials utilized in cells’ cryopreservation; 
 2 mL microcentrifuge tubes. 
 
Purchased to Vector Laboratories, Burlingame, CA, USA 
 The counterstain DAPI used in fluorescent in situ hybridization. 
 
Obtained from Frilabo, Porto, Portugal: 
 2, 5, 10 and 25 mL serological pipettes. 
 
Obtained from Menzel-Gläser, Braunschweig, Germany, through VWR 
International, Lisbon, Portugal: 
 Coverslips and slides, used for immunocytochemistry analysis.  
 
Obtained from Normax, Marinha Grande, Portugal: 
 Coverslips and slides, used for fluorescent in situ hybridization; 
 Coplin jars, used for fluorescent in situ hybridization. 
 
Obtained from Qbiogene, Germany 
 Glue utilized to seal the coverslip used in the fluorescent in situ hybridization. 
 
Obtained from Schleicher & Shuell, Microscience, Dassel, Germany, through 
Reagente 5, Porto, Portugal: 
 0.2µm filters, model FP30 utilized in the sterilization of small volume solutions. 
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2.2    Equipment and software 
 Bench autoclave, model Omega Media from Prestige Medical, Blackburn, UK, 
distributed by Ezequiel Panão Jorge, Electromédica, Coimbra, Portugal; 
 Water purification system, model SimplicityTM from Millipore S.A., Molsheim, 
France, distributed by Interface, Equipamento e Técnica Lda, Amadora, Portugal; 
 Automatic pipetting aid, model ComfoPette from Orange Scientific, Braine-l’Alleud, 
Belgium, distributed by Frilabo, Porto, Portugal; 
 Haemocytometer from Marienfeld, Germany, distributed by Reagente 5, Porto, 
Portugal; 
 Laboratory hotte from Ibérica Industrial Laborum, distibuited by Alfagene, Lisbon, 
Portugal; 
 Heating plate with magnetic stirrer, model Monotherm from Variomag, Daytona 
Beach, Florida, USA; 
 Heating plate, from Stork tronic, Germany; 
 Water bath, model Hyb-bath heating from American Instrument Exchange, Inc., 
Haverhill, MA, USA; 
 Thermal cycler, 96-well VeriFlex ™ Block from Applied Biosystems, Carlsbad, CA, 
USA.     
 pH meter, model HI 110 from Hanna Instruments, Woonsocket, USA, distributed by 
Hanna Instruments Portugal, Póvoa do Varzim, Portugal; 
 Precision weight balance, model Sartorius B P210 S from Sartorius AG, Goettingen, 
Germany, distributed by Sartorius Lda, Lisbon, Portugal; 
 Centrifuge model Heraeus Instruments, Labofuge 400e from Thermo Scientific, 
Waltham, Massachussets, USA, distributed by SupplyLab, Cacém; 
Chapter 2 – Materials and Methods 
39 
 
 Flux cabinet model VBH Compact Cabinet from Steril Manufacturing Division, 
Milan, Italy; 
 Inverted microscope, model Nikon Eclipse TS100 from Nikon, USA, distributed by 
Nikon Portugal, Lisbon, Portugal; 
 CO2 Incubator, model CB150 from Binder-World, New York, USA; 
 96-well multiplate reader spectrophotometer, model SLT Spectra, from Alliance 
Analytical Inc.; 
 Liquid nitrogen storage containers model Forma Cryoplus I from Thermo Scientific, 
Waltham, Massachussets, USA; 
 Ultra-low freezer, model -86C ULT Freezer from Thermo Scientific, Waltham, 
Massachussets, USA; 
 Graphpad QuickCalcs and Graphpad Prism 5, from Graphpad Software, La Jolla, 
California, USA, available free online at the website 
http://www.graphpad.com/quickcalcs/index.cfm; 
 Nikon ACT-1 Software, from Nikon, USA, distributed by Nikon Portugal, Lisbon, 
Portugal; 
 Microscope Photographic Camera, model Nikon Digital Camera DXM 1200F, 
attached to inverted microscope Nikon Eclipse 80i, both from Nikon, USA, 
distributed by Nikon Portugal, Lisbon, Portugal, 
 Fluorescent microscope, from Nikon, USA, distributed by Nikon Portugal, Lisbon, 
Portugal; 
 Digital photographic camera, model T-100, from Olympus, USA, distributed by 
Olympus Portugal, Lisbon, Portugal. 
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2.3 Preparation of solutions  
 
 Tamponized phosphate saline solution (PBS) solutions 
The 10x PBS stock solution is constituted by 2.68 mM of KCl, 4.15 mM of KH2PO4, 
145 mM of NaCl and 8.1 mM of Na2PO4. Following salts solubilization in ultrapure water 
(miliQ water) and just before the final concentration was obtained by miliQ water 
addition, the solution pH was adjusted to 7.4.  
The 1x PBS solution was obtained by diluting the 10x PBS stock solution with miliQ 
water. This solution was sterilized prior to use using an autoclave to avoid contamination 
during cells manipulation and in the preparation of the 1% gelatin solution.  
 
 2 % (w/v) Bovine serum albumin (BSA) solution 
The 2% BSA solution was obtained by powdering 2 g of BSA in 100 mL of miliQ 
water followed by gentle stirring in a magnetic stirrer and subsequent sterilization by 
filtration in a laminar flow chamber. 
  
 2% Gelatin solution  
To obtain this solution, 2 g of gelatin were height and dissolved in a 100 mL of miliQ 
water in a SCHOTT flask. The solution was gently stirred in a hot plate with magnetic 
stirrer to ensure complete dissolution of the gelatin. To help the solubilization process, the 
temperature was slightly increased. Before its use the solution was autoclaved. 
 
 1%Gelatin solution  
To obtain 50 mL 1 % gelatin solution, 25 mL 2 % gelatin solution was mixed with 
Chapter 2 – Materials and Methods 
41 
 
22.5 mL of 1 % PBS and 2.5 mL 1 % BSA solution in a 100 mL SCHOTT flask or in a 
50 mL Falcon tube previously sterilized.  
 
 0,4% (m/v) Trypsin solution  
In order to obtain this solution 400 mg of trypsin were dissolved in 100 mL of 1x 
PBS buffer pH 7.4. 
 
 Ham’s F12 supplemented with Ultroser-G® 
To obtain 100 mL Ham’s F12 with Ultroser-G®, 97 mL of Ham’s F12 was mixed 
with 1 mL of Ultroser-G
®
, 1 mL of penicillin and streptomycin mixture containing 
penicillin at 100 U/mL activity and streptomycin at 100 µg/mL, 1 mL of L-Glutamine and 
100µL of  ampicillin B .   
Note: These additives were stored in frozen aliquots.   
 
 Solutions for G-banding karyotyping  
In classic cytogenetic protocols for human karyotyping, G-banding is routinely used. 
This kind of banding gives standard light and dark bands, which are characteristic for 
each human chromosome.  
 
 Hypotonic solution of 5 mM KCl  
This solution was obtained by dissolution of 0.094 g of KCl in 25 mL of miliQ water.  
 
 Methanol:Acetic acid (1:3) fixation solution  
This solution was obtained by addition of 25 mL of methanol to 375 mL acetic acid, 
followed by homogenization in a magnetic stirrer.  
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 Giemsa solution 10 % 
The 10 % Giemsa solution was obtained by dilution of 10 mL of Giemsa in 90 mL of 
the Gürr buffer pH 6.8.  
 
 
 Phosphate buffer pH 6,8 
This buffer was prepared from the following two stock solutions: 
 Solution A (Stock) 
This solution was obtained by dissolving 13.5 g of H2PO4 in 1.5 L of miliQ water.  
 Solution B (Stock) pH 6.8 
This solution was obtained by dissolution of 11.8 g of Na2PO4 in 1 L of miliQ 
water.  
To obtain the desirable buffer, solution B was gently stirred in a magnetic stirrer. 
Following the insertion of a pH electrode into the solution, solution A was added 
to solution B keeping the agitation to achieve the desirable pH (6.8).  
 
 pH adjustment solution of NaOH 1 M 
This solution was obtained by dilution of 20 g of NaOH in 500 mL miliQ water.  
 
 
 pH adjustment solution of HCl 1 M   
The preparation of this solution consists in dilute 1.74 mL of 37 % HCl in 98.26 
mL miliQ water.  
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 Solution to wash the slides – 10 % FBS in Gürr buffer 
To prepare this solution 10 mL of FBS was added to 90 mL of Gürr buffer, and 
the mixture homogenized carefully in a magnetic stirrer. 
 
 Solutions for Fluorescence In Situ Hybridization (FISH) 
 
 Solution 20x SSC (Sodium chloride/sodium citrate)  
This solution was obtained by dilution of 86.7 g of NaCl and 44.1 g of sodium citrate 
in 500 mL of miliQ water. The solution pH was adjusted to pH 7.0 using concentrated 
HCl, before finalizing water volume. The solution was stored at 4ºC. 
 
 Solution 1x SSC 
To obtain this solution 475 mL miliQ water were added to 25 mL of a 20x SSC 
solution, to obtain a final volume of 500 mL. The solution pH was adjusted to pH 7.0.  
 
 Solution 2x SSC 
To obtain this solution 450 mL of miliQ water were added to 50 mL of a 20x SSC 
solution, to obtain a final volume of 500 mL. The solution pH was adjusted to pH 7.0. 
 
 
 Solution 4x SSC 
To obtain this solution 200 mL of miliQ water were added to 50 mL of a 20x SSC 
solution, to make up a final volume of 250 mL. The solution pH was adjusted to pH 7.0. 
 
 
Chapter 2 – Materials and Methods 
44 
 
 Formamide solution 50% 
In order to obtain this solution an equal volume (20 mL) of formamide 100 % and 2x 
SSC solution were added to obtain a final volume of 40 mL.  
 
 Detergent wash solution (4x SSC/Tween 20) 
To prepare this solution 25 µL of Tween 20 were added to 50 mL of 4x SSC. 
 
 MTT solution for viability assays 
To prepare the MTT 0.5 mg/mL solution, 75 mg of MTT were dissolved in PBS 1x 
in a total of 150 mL. The solution was then divided in aliquots of 10 mL and frozen. To 
prevent contamination of the MTT, the appropriate volume for use during the entire 
experiment was aseptically removed and placed in a separate tube, which was protected 
from light. 
 
 Acid isopropanol 
Acid isopropanol was obtained by addition of 37 % commercial HCl in isopropanol, 
to get a 0,1 M concentration. 
 
 
2.4 Methods 
2.4.1 Cell Culture 
For the purpose of this work, the bronchial epithelial cell line BEAS-2B and 
BEAS-2B-derived cell lines: RenG2, DRenG2, DDRenG2 and Cont1 cells (RenG2 non-
malignant control) were cultured using the appropriated cell culture medium. All cultures 
were implemented under aseptic conditions, preventing contamination with 
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microorganisms, and the cells were incubated, unless otherwise specified, at 37°C in an 
atmosphere with 5% CO2 
 
Conditions and asepsis 
To ensure aseptic conditions, cell culture was performed in a cell culture room 
with proper ventilation, constant temperature and no direct contact with the outside. In 
addition, the presence of UV light allowed its sterilization between utilizations. The flux 
chamber used was a level 2 safety chamber, also equipped with a UV lamp that allowed 
the sterilization of the chamber before and after all the proceedings. 
All the equipment used in the culture room was previously sterilized by means of 
autoclaving, bleaching or 70 % alcohol washing. All the solutions were filtered with 0.2 
µM-sized porous filters before use while all proceedings were performed with sterile 
gloves. 
 
2.4.1.1  Culture of BEAS-2B, Cont1 and RenG2 cell lines 
Each cell line was defrosted from stock vials and plated in T75 cm
2
 flasks pre-
coated with 1 % gelatin (for a minimum of 2h) and containing 14 mL of previously 
warmed LHC-9 medium.  The medium was changed 24 h after cells’ plating and cells 
were allowed to grow in the incubator until they reach nearly 80 % confluence. Once 
reached the desired confluence, culture maintenance was performed as described in 
section 2.4.1.6. 
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2.4.1.2 Culture of DRenG2 and DDRenG2 cell lines 
DRenG2 and DDRenG2 cells were cultured exactly as the previous cell lines, but 
the cell culture media utilized was the Ham’s F12 supplemented Ultroser-G®, whose 
preparation has been described in section 2.3.  
 
2.4.1.3 Cells sub-culturing 
To guarantee the healthy preservation of the cultures, considering their growth rate 
and the fact that the cells’ phenotype can change once confluence is attained, any cell 
culture must be sub-cultured when they reach about 80% confluence.  
Once nearly 80 % confluence was reached, the cell culture medium was discarded and 
the flask was washed with 5 mL of 1x PBS to remove the remnants. 1 mL of trypsin was 
added to detach cells’ from the matrix. When the flask surface was fully covered with 
trypsin, the excess was removed with a pipette, and the flask incubated at 37 ºC for 1 min. 
The flask was then washed with 5 mL of 1x PBS, and the PBS containing the cells was 
collected into a Falcon tube that was subsequently centrifuged for 5 min. at 1500 rpm. 
Following the discharge of the supernatant, the pellet was resuspended in an appropriate 
volume of medium (generally 0.5 mL to 1 mL). Whenever necessary to evaluate the cells’ 
suspension density, a 20 µL aliquot of the cellular suspension was used for cell counting 
with trypan blue assay as described in section 2.4.2. 
 
2.4.2 Cell counting 
To evaluate the cellular density from each cell suspension, a 20 µL sample was 
collected and mixed with an equal volume of 0.4% trypan blue solution. As the dye enters 
into dead cells, because their membranes are damaged, and cells became easily visualized 
by presenting a typical blue color, it will be possible to assess their number. 
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Simultaneously, as living cells are surrounded by dye molecules, they will appear brighter 
which will also allow the evaluation of their exact number.  
A Neubauer chamber, commonly named haemocytometer as it was used to count 
blood cells, was used to count of the cells. This device consists in a special microscope 
slide equipped with a lamella and two wells with a fixed volume of 10
4
µL, divided into 
four equal quadrants.  Each haemocytometer quadrant has the virtual volume of 0.1 mm
3
 
or 0.0001 mL and the haemocytometer contains only half of the cells’ volume removed 
from the original cell suspension as half of the volume was the trypan blue solution. 
Therefore, to calculate the viable cells’ concentration expressed as number of 
cells/volume (mL), the average number of cells were multiplied by 2 (due to dilution 
step) and by 10000 (due to the volume of each quadrant). For cell counting, when the 
cells were at the lines that limit the quadrants, the only ones counted were on the right and 
bottom lines (green lines) (Figure 2.1). Consequently, the cells that were on the left and 
up lines weren’t counted (red lines) (Figure 2.1). With this in mind it was possible to 
determine the cells’ concentration in the original suspension using a Nikon eclipse TS100 
microscope. 
 
 
Fig. 2.1 - Schematic representation of the haemocytometer relation area/volume 
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2.4.3 Cells’ manipulation for cytogenetic studies 
The protocol encompassed several steps namely: (i) cell cycle arrest in pro-
metaphase; (ii) cellular and nuclear swelling; (iii) and successive fixations in order to 
obtain metaphase spreads.  
To obtain adequate metaphase spreads it was crucial to obtain a large number of 
cells in division. To this end, cells were cultured in 75 cm
2
 culture flasks at an initial 
cells’ density of 4000 cells/cm2. When confluence reached 80%, 200 µL of colcemid 
were added and the cells were incubated for 30 min at 37ºC and 5 % of CO2 to induce cell 
cycle arrest in pro-metaphase. During this phase, the chromosomes are condensed and, 
consequently, are easier to be observed in a microscope. The excess colcemid was then 
removed and 4 mL of 1x PBS solution was added to wash the flask content. Once 
discharged the washing solution, 2 mL of trypsin was added to detach cells’ from the 
matrix. To achieve a better efficiency, the flask was incubated for 2 min. at 37 ºC and 5% 
of CO2 (conditions which improves the enzymatic action of the trypsin). The flask content 
was washed twice with 5 mL of PBS 1x solution and the washings collected to Falcon 
tube. The Falcon tube was centrifuged for 5 min. at 1000 rpm to allow cell sedimentation. 
Once the supernatant was discarded, the pellet was resuspended in 1 mL FBS, to inhibit 
possible remains of trypsin to act. Subsequently, 9 mL of an hypotonic solution of KCl 5 
mM were added and the tube was then placed in a stove for 17 min. at 37ºC, to allow the 
KCl to penetrate inside the cells and their nucleus, promoting their swelling.  
After the swelling, several steps of metaphase plaques fixation with 
methanol:acetic acid (3:1) were performed. The first step encompassed a pre-fixation with 
1 mL of fixation solution added to the hypotonic solution. This step was crucial to 
minimize the impact of the fixation solution in the chromosomes, which may compromise 
their structure.  After that, the solution was centrifuged for 5 min. at 1000 rpm, the 
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supernatant was discarded and the pellet was resuspended in 10 mL of fixation solution 
and placed in the freezer during 1 h at 4 ºC. Subsequently, cells were centrifuged for 5 
min. at 1000 rpm, the supernatant was again discarded and the pellet resuspended in 10 
mL of fixation solution. This last step was performed twice, after which the suspension 
was stored overnight at 4ºC.   
 
2.4.3.1 Spreading and banding of metaphase spreads 
The process of cell spreading in slides is crucial to subsequent microscopic analysis. 
During this process, parameters like temperature and humidity have to be carefully 
controlled. The main goal in the spreading is to obtain metaphases with chromosomes 
well disconnected from each other in order to analyze them more easily. To this end it is 
necessary the use of a phase contrast microscope to evaluate the quality of mitoses in the 
slide, as well as to select the better ones.  
  The glass slides were inserted into distilled water. Two drops (7 µL each) of the 
cell suspension were placed at the end of the slide with the aid of a pipettor. The pipettor 
was leaning 30º approximately to the slide. Spreading was performed very gently and 
applied only when there was sufficient liquid on the slide, so that the cells were not 
scratched by the tip. Once spreading was accomplished, the metaphases’ quality was 
observed using a phase contrast microscope.  
Depending on the study the practical approach from here is different. Therefore, 
whenever the chromosomal number alterations were to be evaluated chromosomes were 
stained with 5% Giemsa for 3 to 4 min., followed by several washes with Gürr buffer. 
After drying at room temperature, the slides were ready to be visualized at microscope.  
When the goal was to study the cells’ karyotype, to produce a karyotype by G-
banding, chromosomes were first treated before Giemsa staining. To this end 
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chromosome metaphases were incubated in 0.4 % trypsin to digest the euchromatin zones 
and leave intact the heterochromatin. Chromosomes were then stained with Giemsa, to 
obtain a white and pink banding pattern, corresponding respectively to euchromatin and 
heterochromatin. The white bands have DNA rich in G-C (guanine-cytosine) bases, while 
the pink bands have DNA rich in A-T (adenine-thymine) bases. Every chromosome has 
its unique band pattern which allows their proper identification, as well as, the structural 
alterations by comparison with the reference pattern.      
 In this work, the protocol of G-banding was always used to look for aneuploidies.  
 
2.4.3.2. Karyotypes 
After banding, the best metaphase speads were chosen. These spreads were next 
photographed with the aid of a camera (model LH-100C-1) incorporated in the 
microscope and the images obtained were analyzed with the CytoVision software to 
construct the cells’ karyotype. 
 
 
2.4.3.3 Fluorescence In Situ Hybridization (FISH)  
The FISH protocol used in this work was the whole chromosome painting, more 
specifically the fluorescent in situ hybridization protocol for FITC labeled chromosome 
paints.   
The treatment of metaphase chromosomes, usually prepared 3 days before, 
contemplated the following steps: denaturation, hybridization, washing and detection. To 
this end new slides were prepared with fresh metaphases spreads, which have been fixed 
with 3:1 methanol:acetic acid. Before slides dehydration, they were maintained at 65 ºC 
for 60 min. Slides dehydration was achieved by serial dipping in ethanol for 2 minutes 
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starting with 70 % (v/v) ethanol followed with 85 %, 90 %, and finally 5 minutes in 100 
% ethanol. The slides were then air dried.  
Denaturation was performed by incubating the slides in a 70 % formamide 
solution for 2 min. at 65 ºC (hot plate). The slides were then dipped into ice-cold 70 % 
ethanol (-20 ºC) for 4 min. and dehydrated by serial dipping in ethanol as mentioned 
before. Finally, the slides were allowed to dry.  
As to the probes, following heating to 37 ºC, they were centrifuged and spin-
downed for 1-3 seconds at 6000 rpm. Denaturation was performed by heating at 67 ºC for 
10 min. followed by 60 min. at 37 ºC 
 
Hybridization 
To this end, each probe was added onto the slides and a coverslip applied. 
Carefully, the air bubbles were removed by gently pressing the coverslip before sealing 
with rubber cement. The slides were placed into an air tight, pre-warmed box and 
incubated overnight in the dark at 37 ºC.  
Before washing the slides, all the solutions to be used were pre-heated in a water 
bath at 45 ºC, for at least 30 min. before starting. Once the slides were removed from the 
incubator and the rubber cement taken off, slides were immersed in 2x SSC warmed 
solution to remove the coverslip. The slides were washed by dipping twice for 2 min. in 
warmed 50 % formamide solution, followed by two washes (2 min. each) in warmed 1x 
SSC solution.  The slides were then incubated for 4 min. in warmed detergent solution 4x 
SCC/Tween 20 and drained, before the counterstain solution (DAPI) was applied (10 µL). 
Then, a glass coverslip was applied and the air bubbles removed with the aid of forceps. 
Finally, the counterstain excess was removed by applying pressure on the coverslip. After 
that, the metaphases were observed in a fluorescent microscope (see section 2.2), and 
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were photographed with the aid of a camera (model LH-100C-1) incorporated in the 
microscope: The obtained images were treated with the CytoVision software.     
 
2.4.4. Immunocytochemistry  
Immunocytochemistry allows the identification of a specific antigen in a 
cytological preparation using an antigen-specific antibody. The localization of the 
primary antibody (and therefore the target antigen) is then visualized microscopically via 
a specific enzymatic or fluorescent detection system.   
This method which encompasses three distinct steps, cell growing, fixation and 
finally, antibody staining, was used to evaluate the expression of Vimentin, Cytokeratins, 
Oct3/4 and P-Glycoprotein in all the five cells lines (BEAS-2B, Cont1, RenG2, DRenG2 
and DDRenG2).    
Two slides, previously sterilized by dipping in 100 % ethanol, were inserted in 
sterile Petri dishes and 5 mL of 1 % gelatin was added at least 2 h prior to the addition of 
the cells. Before plating the cells at an initial density of 4000 cells/cm
2
, the Petri dish was 
washed with 5 mL of 1x PBS and 10 mL of each cell line specific cultivation medium 
were added. Thereafter, the cells were grown until the optimal cell confluence was 
achieved. The Petri dishes were observed frequently and during this time the medium was 
regularly changed to allow better growth conditions. 
Once cultures reached nearly 80 % confluence, the medium was removed and the 
cells were washed 3 times with 5 mL 1x PBS. Once the slides were properly identified 
(initials, cell culture line, and date), they were placed into 50 mL Falcon tubes filled with 
95% ethanol and allocated in the freezer.  This process may cause a conformational 
change in the tertiary structure of proteins, therefore it may difficult the antigen-antibody 
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interaction, in particular when using a cross-linking fixative. So, sometimes is necessary 
to use mechanisms of antigen retrieval.       
Afterwards, the endogenous peroxidase activity was quenched using 15 min. 
incubation in 3 % diluted hydrogen peroxide (H2O2). For blocking the nonspecific 
binding with primary antibodies, slides were first dipped in Ultra V Block, from the Ultra 
Vision Kit, for 5 min. For the staining with primary antibodies, different dilutions were 
used, according to the manufacturers; for Cytokeratin (MNF116) a dilution of 1:50 was 
used, for Vimentin the dilution was 1:200, for Oct3/4 1:100 and for P-glycoprotein 1:20. 
After adding the primary antibody, the slides were incubated at room temperature for 30 
min. in the case of the first two antibodies and for 30 minutes and 60 minutes, in the case 
of Oct3/4 and P-glycoprotein, respectively. The slides were then washed with PBS from 
the Ultra Vision Kit, and incubated 15 min. with biotin-labeled secondary antibody, 
commercialized as part of the Ultra Vision Kit. Primary antibody binding was localized 
using peroxidase-conjugated streptavidin (Ultra Vision Kit) and 3,3-diaminobenzidine 
tetrahydrochloride (DAB) was used as chromogen, according to manufacturer’s 
instructions. Hematoxylin was used to counterstain the slides which were then dehydrated 
and mounted. In parallel, known positive and negative controls were used. The intensity 
of the staining was graded semi-quantitatively on a four point scale (0;1+,2+,3+). The 
percentage of immunostained cells was also registered. A final score was obtained 
multiplying the intensity by the percentage of cells with immunohistochemical expression 
and the cut off considered was 10% positive cells.   
Finally, the slides were visualized with an inverted-phase microscope and 
photographed with the aid of a camera incorporated (Digital Camera DXM 1200F) in the 
microscope.        
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2.4.5. Cell doubling times  
To evaluate the duplication times of the different cell lines, cells were cultured in 
T75
 
culture flasks at an initial cells density of 4000 cells/cm
2
 and using the appropriated 
culture medium (LHC-9 or F12 with UG) as described in section 2.4.1. Once confluence 
reached nearly 80 %, the medium was discarded, and the flasks washed with 6 mL of 1x 
PBS to remove the remnants. 2 mL of trypsin was added to detach cells from the matrix. 
When the flasks’ surfaces were fully covered with trypsin, the excess was removed with a 
pipette, and the flasks were incubated at 37 ºC for 1 min. The flasks were then washed 
with 15 mL of 1x PBS, and the cells suspension was collected into Falcon tubes and 
centrifuged for 5 min. at 1500 rpm. After discarding the supernatant, the pellets were 
resuspended in appropriated volumes of medium (generally 0.5 mL to 1 mL) and 20 µL 
aliquots were removed from each suspension to assess the number of cells by the trypan 
blue assay as described in section 2.4.2.  
After expanding the cultures, to evaluate cells’ duplication times an appropriated 
volume of the cell suspensions were transferred to 6 well multiwell plates (MW6) to 
obtain an equal initial density of 3.8x10
4
 cells/mL (4000 cells/cm
2
) in each well. For each 
time point at least 3 wells per cell line were used.  
The cells were counted in four different time points, at 24 h, 48 h, 60 h and the 
final count at 72 h. However, the analysis of cells’ duplication times only started during 
the exponential phase (log phase), when the cells have reached the optimum growth 
conditions.  
In each time point the cell culture medium was discarded and the wells washed 
with 1 mL of 1x PBS to remove the remnants. 0.4 mL of trypsin was added to detach cells 
from the matrix. When the wells’ surface was covered with trypsin, the excess was 
removed with a pipette, and the MW plate incubated at 37 ºC for 1 min. Each well was 
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washed with 2 mL of 1x PBS, and each cellular suspension was collected into a Falcon 
tube and centrifuged for 5 min. at 1500 rpm. Following the discharge of the supernatant, 
the pellet was resuspended in an appropriate volume of medium (generally 0.5 mL to 1 
mL). To evaluate the cells’ suspension density a 20 µL aliquot of the cells’ suspension 
was used for cell counting with trypan blue assay as described in 2.4.2. 
To evaluate whether the differences of doubling times between cell lines were 
statistically significant, the Graphpad Quickcalcs and Graphpad Prism 5 was used.     
 
 
2.4.6 Drug resistance assays  
 
The MTT assay, a safe, sensitive and reliable method to examine cells’ viability, 
was used to evaluate the resistance of cells to the mostly widely used anti-neoplasic drugs 
such as GEM and cDDP. The yellow tetrazolium compound MTT is reduced, mainly by 
mitochondrial dehydrogenases of metabolically active cells, to insoluble purple formazan 
dye crystals. 
The cells were cultured in T75 culture flasks at an initial density of 4000 cells/cm
2
 
and using the appropriated culture medium (LHC-9 or F12 with UG) as described in 
section 2.4.1. Once confluence reached nearly 80 %, the cells sub-culturing protocol, 
described in 2.4.1, was used.  After expanding the cultures, an appropriated volume of the 
cells’ suspensions was transferred to 24 well multiwell plates (MW24) to obtain an initial 
density of 1.52x10
4
 cells/mL (8000 cells/cm
2
), in each well. For each cell line 3 controls, 
plus triplicates for each drug concentration were used. Besides that, in each plate 3 wells 
were left only with medium (negative control - blank). 24 h after plating 10 µL of the 
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desired drug concentrations (0.1 µM, 10 µM and 50 µM) were added and during the 
following 3 days, MTT readings were made (Figure 2.2).   
Before each MTT reading, the medium was discarded and the wells were washed 
with 200 µL of 1x PBS to remove the remnants. After that, 500 µL of MTT 0.5 mg/mL 
were added. Thereafter, the cells were incubated for 3 to 5 hours at 37 ºC and in 5 % of 
CO2. The MTT solution was carefully removed to avoid the removal of the violet 
formazan crystals, and 500 µL of acid isopropanol were added to dissolve the formed 
crystals. The absorbance was measured at 570 nm, in a multiplate reader, using the 620 
nm as the reference wavelength.  
 
 
 
 
 
 
 
 
 
Figure 2.2 Schematic representation of the in vitro studies made to determine the anti-
proliferative activity of the cDDP and GEM.  
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As the tetrazolium reduction is proportional to the cells’ viability, the changes in 
cells’ viability induced by each specific drug concentration were determined in relation to 
the control using the equation (1).  
% cell viability = 
        
         
 x 100   Equation 1 
 
In this equation, 𝝺 sample represents the wavelength of the cells’ sample exposed 
to the drug under evaluation, minus the wavelength of the blank (acid isopropanol), while 
𝝺 control represents the wavelength of the controls (cells without drug), minus the 
wavelength of the blank.   
 
 
 
2.5. Statistical analysis  
The results obtained were analyzed in the Graphpad Prism 5.00 program.  The 
represented results are the mean ± standard deviation.  
In the analysis of the obtained data, the statistic treatment was carried out by One-
Way ANOVA method followed by the Dunnet’s test (vs control cultures).  
When aiming to see the differences between the different drugs used and their 
different concentrations, the method used was the One-Way ANOVA followed by Tukey 
test.      
  
 
 
 
 
 
 
 
 
3. Results 
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Cancer cells are characterized by a variety of genomic defects, such as, 
inactivation of DNA repair genes, over-expression of growth promoting oncogenes, extra 
or missing chromosomes, abnormal number of centrosomes and aberrant mitoses and 
citokinesis (Meraldi et al., 2004), which lead some authors to classify it as the disease of 
genes (Shipitsin and Polyak, 2008). As a consequence of this definition, when studying 
cancer in vitro, through the use of different cell lines, is of extreme importance to 
characterize all the cellular systems under study in order to identify chromosome 
alterations (structural and/or numeric) that could ultimately unveil the gene alterations 
that drove the malignant process (i.e. tumor suppressor genes and oncogenes).  
 Recently, in our lab we observed, using the non-tumorigenic BEAS-2B cell line, 
immortalized with an adenovirus 12 and a Simian virus (SV40) viral hybrid, and their 
malignant derivatives RenG2, DRenG2 and DDRenG2, an unexpected degree of 
plasticity between stem-like and non-stem cell compartments, leading to the 
demonstration that differentiated cell types can convert to stem-like cells. In the light of 
these results it was undertaken the study of the biology of the populations of cells RenG2, 
obtained following prolonged treatment with Cr(VI), a known lung carcinogenic agent, of 
differentiated non-tumorigenic bronchial epithelial cells,  (BEAS-2B), and DRenG2 and 
DDRenG2 cells obtained out of tumours induced in athymic nude mice by RenG2 and 
DRenG2 cell lines respectively. 
A previously analyse of BEAS-2B cells showed an isochromosome 5 [i(5)(q10)], 
a terminal deletion of the short arm of chromosome X (Xp-) and additional material on 
the short arm of chromosomes 15 (15p+), 16 (16p+) and 22 (22p+) (Rodrigues et al., 
2009). In addition, this cell line exhibited a trisomy of chromosome 20 in nearly 80% of 
the metaphases analysed, the presence of a derivative chromosome 14 with additional 
material on the short arm [der(14)] on 70% of the metaphases, as well as structural 
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alterations of the banding pattern along the long arm of chromosome 2 [der(2)] on 20% of 
the metaphases (Rodrigues et al., 2009). As to the first malignant BEAS-2B-derivative 
cell line, RenG2, showed a marked karyotypic change with an aneuploid phenotype (ca. 
80 chromosomes in over 90% of the metaphases analyzed) (Rodrigues et al., 2009).  
 
3.1 Cytogenetic characterization  
In our lab the precursor cell lines, namely BEAS-2B and RenG2 cells have already 
been characterized, and so, the next step was the characterization of the DRenG2 and the 
DDRenG2 cell lines.  
 The first step to assess the characterization of these cell lines was taken by using 
conventional cytogenetic analysis (karyotype), followed by FISH.       
The karyotypic characterization was made at the passage #27, #33 and #34 of 
DRenG2 and at the passages #30, #32, #33 and #34 of DDRenG2 cells. The FISH 
characterization was made at the passage #21 of DRenG2 cell line.  
As to the G-Banding karyotype analysis, once obtained medium/high quality 
metaphase plaques, microscope observation allowed the evaluation of the numeric and 
structural alterations characteristic of each cell line using at least good quality 15 
kariotypes for each cell line. The G-Banding results revealed that both DRenG2 and 
DDRenG2 cell lines predominant ploidy was 75/76 chromosomes with some 
chromosomes portraying a numeric pattern, in other words, these numeric alterations 
appear almost in all the metaphases. However, some other chromosomes have more than 
one numeric alteration.  For both cell lines, no numeric changes were observed along 
passages.  
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3.1.1 DRenG2 cell line characterization     
3.1.1.1 Karyotype 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1 A representative karyotype of DRenG2 cell line (#33) 
.    
 
Karyotype analysis revealed that DRenG2 cell line had the characteristic 
isochromosome 5 [i(5)(q10)], already reported for BEAS-2B cell line (Rodrigues et al., 
2009), present in 87% of the metaphases analysed. Other alterations that have been 
already reported in BEAS-2B and RenG2 cell lines (Rodrigues et al., 2009) and that 
appear in this cell line were the additional material on the short arm of chromosome 15 
(15p
+
) and the presence of a derivative chromosome 14 with additional material on the 
short arm [der(14)] on 73% of the metaphases as well as structural alterations of the 
banding pattern along the long arm of chromosome 2 [der(2)] on 20% of the metaphases 
(Rodrigues et al., 2009). The translocation between the chromosomes 16 and 17 
[t(16;17)] and between the chromosomes 21 and 22 [t(21;22)], which appear in 80% and 
22p
+
 22p
+
 
der(14) 
t(16;17) 
i(5)q(10) 
der (2) 
7q
-
 
i(9)(q+) 
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87% of the metaphases analysed, respectively, were also present in both BEAS-2B and 
RenG2 cell lines (Rodrigues et al., 2009). However, new structural alterations, specific 
for DREnG2 cell line, were observed i.e., the terminal deletion of the long arm of the 
chromosome 7 (7q
-
), and an isochromosome 9 [i(9)(q
+
)], were identified  in 20% and 60% 
of the metaphases analysed, respectively (Figure 1 and Table I). 
     
Table I. The numeric and structural alterations observed in the DRenG2 cell 
line. 
Chromosome Numeric alterations  Structural alterations 
1 4 (80%); 3 (20%) - 
2 3 (87%); 4 (13%) der(2) (20%) 
3 4 (80%); 3 (20%) - 
4 2 (60%); 3 (40%) - 
5 3 (100%) i(5)(q10) (100%) 
6 3 (87%); 4 (6.5%); 2 (6.5%)  - 
7 4 (53%); 3 (40%); 5 (7%) 7p
- 
(40%); 7q
-
 (20%) 
8 3 (73%); 4 (27%)  - 
9 3 (53%); 2 (47%) i(9)(q
+
) (60%) 
10 4 (73%); 3 (27%) - 
11 2 (33.3%); 3 (33.3%); 4 (33.3%) - 
12 4 (60%); 3 (27%); 2 (13%) - 
13 3 (53%); 2 (47%) - 
14 3 (60%); 2 (27%); 4 (13%)  der(14) (60%) 
15 3 (60%); 2 (27%); 1 (13%) 15p
+ 
(60%) 
16 4 (60%); 3 (40%) t(16;17) (73%) 
17 3 (87%); 2 (13%) - 
18 3 (87%); 1 (13%) - 
19 3 (67%); 2 (27%); 4(6%) - 
20 4 (60%); 3 (40%) - 
21 4 (60%); 3 (33%); 5 (7%) t(21;22) (80%) 
22 4 (40%); 3 (33%); 5 (14%); 2 (13%) 22p
+
 (73%) 
X 1 (100%) - 
Y 0 0 
 
Regarding numeric alterations, some chromosomes display a numeric pattern; in 
other words, these numeric alterations appear almost in all the observed metaphases. On 
the other hand, some chromosomes show more than one numeric alteration.  
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3.1.1.2 - Fluorescence in situ hybridization (FISH) 
Since the G-Banding karyotype analysis revealed some uncertainties concerning 
chromosomal structural alterations in order to, tentatively, solve these problems, another 
technique was used. This technique, called fluorescent in situ hybridization or FISH, is 
used mainly to detect and localize the presence or absence of specific DNA sequences on 
chromosomes. To accomplish this objective, fluorescent probes that bind to only those 
parts of the chromosome with which they have a high degree of sequence complementary 
are used (Langer-Safer et al., 1982).   
Figure 3.2 consistently illustrates the presence, in DRenG2 cell line, of four 
chromosomes 1 (red) in accordance with G-Banding karyotype analysis. Importantly, 
FISH analysis revealed the presence in this cell line of two complete chromosomes 17 
(green) and two halves of this same chromosome (Figure 3.2) with an additional portion 
of the chromosome 16. These t(16;17) has also been observed by G-Banding analysis.  
 
 
 
Figure 3.2 Representation of a DRenG2 cell line metaphase with an 
amplification of 400x. The chromosomes painted, are the chromosome 1 (red) and 
17 (green). 
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Figure 3.3 Representation of a DRenG2 cell line metaphase with an 
amplification of 400x. The chromosome painted in green is the chromosome 15. 
 
 
Figure 3.3 illustrates FISH analysis of chromosome 15. The image illustrated 
revealed the presence of an entire chromosome 15 and the presence of two other 
chromosomes with additional material that not belongs to chromosome 15. All 
chromosomes appear to have different sizes. FISH analysis corroborates what was 
depicted in the Table I, since 60% of the metaphases appear to have a chromosomal 
alteration 15p
+ 
 
 
 
 
 
 
 
 
 
Chapter 3 - Results 
67 
 
3.1.2 DDRenG2 cell line characterization 
3.1.2.1 Karyotype 
  
 Fig. 3.4 A representative karyotype of DRenG2 cell line (#33) 
 
Similarly to DRenG2 also some of DDRenG2 cell line structural characteristics 
have been also reported previously for BEAS-2B and RenG2 cell lines (Rodrigues et al., 
2009), namely [i(5)(q10)], additional material in chromosomes 15 and 22 i.e., 15p
+
 and 
22p
+
, derivative chromosome 14 with additional material on the short arm [der(14)] 
(Tables I and II). The translocations [t(16;17)] and [t(21;22)] were simultaneously present 
in both DRenG2 and DDRenG2 cell lines, although in different percentages (Tables I and 
II). 
Regarding de novo alterations, a translocation between the chromosomes 7 and 14 
[t(7;14)] and a derivative of chromosome 17 with addition material on its short  arm 
(17q
+
) were identified in 40% and 27% of the metaphases analysed, respectively (Figure 
7p
-
 
15p
+
 
t(21;22) 
t(16;17) 
t(7;14) 
i(5)(q10) 
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3.4). Because they are being identified in our systems for the first time, we assume these 
alterations to be characteristic of the DDRenG2 cell line. Finally, another alteration 
observed was a terminal deletion of the short arm of the chromosome 7 (7p
-
), which also 
appears in some metaphases of the DRenG2 cell line (Table II). Unlike DRenG2, the 
additional material on the short arm of chromosome 17q
+ 
is present in DDRenG2 cell line 
(Tables I and II). 
  Characteristic of both DDRenG2 and DRenG2 cell lines was the absence of 
chromosome Y (Figures 3.1 and 3.4). 
As for the previous cell line, also here the numeric alterations for some 
chromosomes are variable, while others appear to have a particular pattern.  
 
Table II. The numeric and structural alterations observed in the DDRenG2 cell line 
Chromosome Numeric alterations  Structural alterations 
1 4 (87%); 3 (13%) - 
2 3 (80%); 4 (20%) - 
3 4 (87%); 3 (13%) - 
4 3 (73%); 2 (23%) - 
5 3 (93%); 2 (7%) i(5)(q10) (87%) 
6 3 (100%) - 
7 4 (60%); 3 (40%) 7p
-
 (27%); t(7;14) (40%) 
8 4 (80%); 3 (20%) - 
9 3 (100%) - 
10 3 (87%); 2 (13%) - 
11 3 (53%); 4 (33%); 2 (14%) - 
12 3 (73%); 4 (27%) - 
13 3 (73%); 2 (27%) - 
14 3 (67%); 2 (33%) der(14) (73%) 
15 3 (80%); 2 (20%) 15p
+
 (73%) 
16 3 (87%); 4 (13%) t(16;17) (80%) 
17 3 (67%); 4 (33%) 17q
+ 
(27%) 
18 2 (87%); 3 (13%) - 
19 3 (73%); 2 (14%); 1 (13%) - 
20 4 (80%); 2 (20%) - 
21 4 (80%); 5(7%); 3 (13%) t(21;22) (80%) 
22 3 (60%); 4 (40%) 22p
+
 (73%) 
X 1 (100%) - 
Y 0 0 
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3.2. Characterization by immunocytochemistry of the BEAS-2B, Cont-1, 
RenG2, DRenG2 and DDRenG2 cell lines 
 
As described in Chapter 1, we and others observed that differentiated cell types acquired 
an unexpected degree of plasticity, possibly via an EMT process (Rodrigues et al., 2011; Chaffer 
et al., 2011).  So, following the cytogenetic characterization of the DRenG2 and DDRenG2 cell 
lines it was crucial to evaluate the presence or absence of biomarkers specific of the epithelial and 
mesenchimal phenotypes. To this end the BEAS-2B cell line and its derivative cell lines i.e., 
RenG2, DRenG2, DDRenG2, and Cont-1 were characterized by immunocytochemistry to assess 
their epithelial/mesenchymal status [MNF 116, Vimentin] and the presence of cancer stem 
cells biomarkers i.e. the simultaneous presence of Oct-4 (stem-like), and P-Glycoprotein 
(transport system-resistance to chemotherapy).  
As depicted in Table III and Figures 3.5-3.8 all cell lines had fusiform and polygonal 
small cells. However the DDRenG2 cell line possessed also mononucleated large cells (Figure 
3.6).  
The BEAS-2B cell line had great number of mitotic cells and, surprisingly, like the all 
others cell lines it has naked nucleus i.e., cells with loss of cytoplasm (Figures 3.5-3.8).   
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Table III. Table representing the immunocytochemistry analysis for the five cell lines. 
(+++, >75% of cells stained; ++, 50%-75% of cells stained; +, 10%-50% of cells stained, -, 
there aren’t cells stained) 
 
 MNF116 Vimentin Oct3/4 P-gp Description 
BEAS-2B ++ + / - Fusiform and polygonal small cells  
Presence of mitotic cells  
Cont-1 ++ + / - Fusiform and polygonal small cells  
RenG2 ++ ++ / - Fusiform and polygonal small cells 
DRenG2 +++ ++ - -  
Fusiform and polygonal small cells 
DDRenG2 +++ +++ - - Fusiform and polygonal small cells 
Mononucleated large cells are also present  
 
 
 
Figure 3.5 Representative images of immunocytochemical staining of BEAS-2B 
(A, B).  and Cont-1 cell lines (C,D). Cells had been previously plated on top of 
microscopic slides for staining later on for Cytokeratin (MNF 116) (A and C 400x) 
and Vimentin (B and D 400x) as described in Materials and Methods. The blue 
colour represents the cell nucleus and the brown colour the antibody staining.  
A 
A B 
C 
D 
D 
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As illustrated in Figure 3.5 the non-malignant BEAS-2B and Cont-1 cell lines 
stained positive for both antibodies even though, less than 50% of the cells stained 
positive for Vimentin. The higher expression of Cytokeratins revealed that the vast 
majority of the cells in both cell lines have an epithelial phenotype.  
 
Figure 3.6 Representative images of immunocytochemical staining of RenG2 (A, 
B), DRenG2 (C, D) and DDRenG2 cell lines (E, F). Cells had been previously 
plated on top of microscopic slides for staining later on for Cytokeratin (MNF 116) 
(A and E 200x, C 400x) and Vimentin (B 400x, D and F 200x) as described in 
Materials and Methods. In blue are represented the cell nucleus and in brown the 
antibody staining.  
A B 
D C 
E F 
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As illustrated in Figure 3.6 RenG2, DRenG2 and DDRenG2 cell lines stained 
positive for both antibodies (MNF 116 and Vimentin). The more malignant cell lines, 
DRenG2 and DDRenG2, have more than 75% of the cells medium to high staining for the 
mesenchymal antibody (Vimentin), respectively.  However, DRenG2 revealed a higher 
staining for MNF116 (Figure 3.6 C) than for Vimentin (Figure 3.6 D). On the other hand, 
the RenG2 cell line has a medium staining for both antibodies, with 50% to 75% of the 
cells stained.  
These results just confirmed the presence, in each cell line, of different sub-
population of cells with either epithelial or mesenchymal phenotypes.   
 
 
Figure 3.7 Representative images of immunocytochemical staining of DRenG2 
(A), DDRenG2 (B). Cells had been previously plated on top of microscopic slides 
for staining later on for P-gp (A 100x and B 40x) as described in Materials and 
Methods.  
 
 
 
As illustrated in Figure 3.7 both DRenG2 and DDRenG2 cell lines stained negative 
for the P-gp antibody. The same was observed for the BEAS-2B, Cont-1 and RenG2 cell 
lines (image not shown).   
 
 
 
A 
B 
B 
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Figure 3.8 Representative image of immunocytochemical staining of DDRenG2 
(A). Cells had been previously plated on top of microscopic slides for staining later 
on for Oct3/4 (A 200x) as described in Materials and Methods.  
 
 
 As illustrated in Figure 3.8 the DRenG2 cell line stained negative for the Oct3/4 
antibody (image not shown). The same was observed for the DDRenG2 cell line.   
 
 
 
3.3. Duplication time of BEAS-2B, Cont1, RenG2, DRenG2 and DDRenG2 
cell lines     
 
 
Cancer cells are commonly thought to have high proliferation rates even though 
that is not always the case. In what concerns CSCs quite often are in a quiescent non-
proliferative state (Alison et al., 2012). Aiming to evaluate whether the more malignant 
phenotypes were more proliferative than their less malignant (RenG2) counterpart, the 
doubling times of all cell lines including the non-malignant BEAS-2B and Cont-1 cell 
lines were evaluated using the trypan blue assay. Analysing the graphs illustrated in 
Figures 3.7 and 3.8 it is possible to observe that, even though, the lag phase lasted 
approximately 48h for all the cell lines the exponential growth phase slope was steeper 
for the more malignant cell lines i.e., DRenG2 and DDRenG2. Accordingly, as illustrated 
in Figure 3.12, the more malignant cell lines DRenG2 (17.04±0.38 h), and DDRenG2 
A 
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(18.86±0.21 h), have statistically significant lower duplication times than their less 
malignant counterpart RenG2 (21.83±0.5 h) and the non-malignant BEAS-2B and Cont-1 
with 23.16±0.42 h and 23.03±0.16 h, respectively.    
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Figure 3.9 Cell doubling time of the BEAS-2B, Cont-1, RenG2, DRenG2 and 
DDRenG2 cell lines. This graph represents the number of viable cells versus the 
incubation time (72h). The number of cells was calculated by the trypan blue method 
as described in section 2.4.5. For each day, the number of cells obtained is the mean 
of the values measured in triplicates.   
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Figure 3.10 Graphic representation of the duplication time from 5 different cell lines 
(Beas-2B, Cont-1, RenG2, DRenG2 and DDRenG2). The results are presented as the 
mean of three independent experiences (± standard deviation). *p<0.05, **p<0.01, 
#
p<0.001 
 
 
 
 
 
3.4. Drug resistance/ cell viability  
The current therapies used in cancer treatment quite often aren’t effective to 
complete eradication of the disease, mostly because either the disease is in a very 
advanced stage and/or the existence of tumour subpopulations, such as the cells with 
stem-like properties i.e., CSCs, highly resistant to therapies. Current cell lines used in the 
labs (either commercial or primary cultures established from human and animal tissues) 
are non-homogenous representing, in a very small scale, the cellular heterogeneity 
observed in the tissues. As a matter of fact, the commercial BEAS-2B cell line is not 
homogenous and the same was observed for its derivatives, the non-malignant Cont-1 and 
the malignant counterparts RenG2, DRenG2 and DDRenG2 (results not shown). The 
most recent studies on going on our lab with these cell lines revealed the presence of 
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# 
** 
 # 
subpopulations of CSCs only in the more malignant cell lines DRenG2 and DDRenG2. 
Thus, the need to evaluate the resistance of all the five cell lines to the most widely used 
chemotherapeutic drugs against lung cancer (gemcitabine and cisplatin) to assess whether 
the resistance can be credited to the presence of CSCs subpopulations. To this end, 
several experiments were conducted adding either 0.1 µM, 10 µM and 50 µM cisplatin or 
gemcitabine to each cell line culture 24h after plating and evaluating the cells’ viability, 
using the MTT assay as described in section 2.4.6, at 24h, 48h and 72 h after drugs 
addition.  
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Figure 3.11 Different drug concentration effects (0.1µM, 10µM and 50µM) 
in the cell viability at 3 different times of drug exposure (24h, 48h, and 72h) 
for the BEAS-2B cell line, determined by the MTT assay. The results are 
represented as percentages in relation to the obtained control values. In this 
graph, it is also represented some statistically differences between drug 
concentrations and between both drugs. All the cultures were prepared with 
an initial cell density of 8x10
3
cells/cm
2
. For each condition, the results are 
presented as the mean of three independent experiences (± standard 
deviation). *p<0.05, **p<0.01, 
#
p<0.001 
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Figure 3.11 reveals that exposure of BEAS-2B to either cisplatin or gemcitabine 
decreased significantly the cells’ viability 24h following the each drug addition. The 
drugs’ effects were concentration dependent with particular emphasis for 50 M 
gemcitabine. Figure also illustrates that for the highest concentration tested (50µM) 
gemcitabine was significantly more effective in decreasing cells’ viability than cisplatin. 
However, independent of the drug and concentration tested BEAS-2B cells didn´t survive 
to exposures longer than 24h. 
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Figure 3.12 Different drug concentration effects (0.1µM, 10µM and 50µM) 
in the cell viability at 3 different times of drug exposure (24h, 48h, and 72h) 
for the BEAS-2B cell line, determined by the MTT assay. The results are 
represented as percentages in relation to the obtained control values. In this 
graph, it is also represented some statistically differences between drug 
concentrations and between both drugs. All the cultures were prepared with 
an initial cell density of 8x10
3
cells/cm
2
. For each condition, the results are 
presented as the mean of three independent experiences (± standard 
deviation). *p<0.05, **p<0.01, 
#
p<0.001 
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Concerning Cont-1 cell line the treatment with either cisplatin or gemcitabine 
decreased significantly the cells’ viability 24h following the each drug addition. The 
drugs’ effects were concentration dependent with particular emphasis for 50 M 
gemcitabine at 24h of drug exposure. At 50µM after 24h of exposure the most effective 
drug (more pronounced decrease in cell viability) was the gemcitabine, however after 48h 
of drug exposure there wasn’t significant statistically differences between the drugs.  
Independent of the drug and concentration tested Cont-1 cells didn´t survive to 
exposures longer than 48h. 
In both cell lines there were significant statistically differences (P<0.001) in cells 
between the control and the cells that were exposed to cisplatin and gemcitabine for 24h, 
48h and 72h, independent of the drugs concentration used (graph not shown).  
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Figure 3.13 Different drug concentration effects (0.1µM, 10µM and 50µM) 
in the cell viability at 3 different times of drug exposure (24h, 48h, and 72h) 
for the RenG2 cell line, determined by the MTT assay. The results are 
represented as percentages in relation to the obtained control values. In this 
graph is also represented some statistically differences between drug 
concentrations and between both drugs. All the cultures were prepared with 
an initial cell density of 8x10
3
cells/cm
2
. For each condition, the results are 
presented as the mean of three independent experiences (± standard 
deviation). *p<0.05, **p<0.01, 
#
p<0.001 
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As to the RenG2 cell line there was also significant statistically differences 
(P<0.001) in cells between the control and the cells that were exposed to cisplatin and 
gemcitabine for 24h, 48h and 72h, independent of the drugs concentration used (graph not 
shown). The drugs’ effects on cells’ viability were also much pronounced for longer 
exposures i.e., 48 and 72h particularly for 72h exposures, with just 20-15% cells alive, 
even though, for 72h exposure to cisplatin the effects were not significantly dependent on 
its concentrations. Also, between the dose concentrations of 0.1 µM and 10 µM, there 
were only significant concentration differences for gemcitabine exposure at 24h (P<0.01). 
The results of Figures 3.11 and 3.12 for BEAS-2B and Cont-1 cells, respectively and the 
ones illustrated in Figure 3.13 for RenG2 cells clearly show that RenG2 cells are more 
resistant to both cisplatin and gemcitabine. Also, in contrast to BEAS-2B and Cont-1 
cells, which were significantly less resistant to the highest gemcitabine concentration, 
RenG2 cells were similarly resistant to gemcitabine and to cisplatin. 
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Figure 3.14 Different drug concentration effects (0.1µM, 10µM and 50µM) 
in the cell viability at 3 different times of drug exposure (24h, 48h, and 72h) 
for the DRenG2 cell line, determined by the MTT assay. The results are 
represented as percentages in relation to the obtained control values. All the 
cultures were prepared with an initial cell density of 8x10
3
cells/cm
2
. For each 
condition, the results are presented as the mean of three independent 
experiences (± standard deviation). *p<0.05, **p<0.01, 
#
p<0.001 vs control 
 
 
Concerning DRenG2 cell line, Figure 3.14 illustrates that exposure to both 10 M 
and 50 M cisplatin or gemcitabine significantly decreased the cells’ viability in relation 
to the control, particularly relevant for 72h exposures (P<0.001). The cells’ viability at 
24h and 48h is almost the same, particularly evident for 48h exposure to gemcitabine 0.1 
µM. Figure 3.15 also illustrates that for the shorter exposure (24h) to 10 M and 50 M 
gemcitabine there is little statistical difference (p<0.05). Surprisingly, and in contrast to 
BEAS-2B, Cont-1 and RenG2, it is noticeable that DRenG2 is more resistant to 
gemcitabine than to cisplatin, particularly for longer exposures i.e., 72h (Figure 3.15). 
Clearly, when comparing the results expressed in previous Figures 3.11-3.13 is evident 
that DRenG2 cell line is significantly more resistant to both drugs concentrations 
particularly for 72h exposures.  
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Figure 3.15 Different drug concentration effects (0.1µM, 10µM and 50µM) 
in the cell viability at 3 different times of drug exposure (24h, 48h, and 72h) 
for the RenG2 cell line, determined by the MTT assay. The results are 
represented as percentages in relation to the obtained control values. In this 
graph is also represented some statistically differences between drug 
concentrations and between both drugs. All the cultures were prepared with 
an initial cell density of 8x10
3
cells/cm
2
. For each condition, the results are 
presented as the mean of three independent experiences (± standard 
deviation). *p<0.05, **p<0.01, 
#
p<0.001 
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Figure 3.16 Different drug concentration effects (0.1µM, 10µM and 50µM) 
in the cell viability at 3 different times of drug exposure (24h, 48h, and 72h) 
for the DRenG2 cell line, determined by the MTT assay. The results are 
represented as percentages in relation to the obtained control values. All the 
cultures were prepared with an initial cell density of 8x10
3
cells/cm
2
. For each 
condition, the results are presented as the mean of three independent 
experiences (± standard deviation). *p<0.05, **p<0.01, 
#
p<0.001 vs control 
 
Concerning DDRenG2 cell line, Figure 3.14 illustrates that exposure to both 10 
M and 50 M cisplatin or gemcitabine significantly decreased the cells’ viability in 
relation to the control (p<0.001), however despite this difference in cell viability in 
relation to the control, the DDRenG2 cell line, presented a higher cell viability at 72h of 
exposure than the DRenG2 cell line.   
The cells’ viability during the three days of exposure is almost the same, 
particularly evident for gemcitabine and cisplatin 0.1. Figure 3.15 also illustrates that for 
shorter exposures (24h and 48h) to 0.1 M and 10 M gemcitabine there is no statistical 
differences between them. In accordance with the DRenG2 cell line, DDRenG2 cell line 
is more resistant to gemcitabine than to cisplatin, particularly for longer exposures i.e., 
72h (Figure 3.17). From the cell lines mentioned before, the cell which has higher cell 
viability is the DDRenG2 cell line.  
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 Figure 3.17 Different drug concentration effects (0.1µM, 10µM and 50µM) 
in the cell viability at 3 different times of drug exposure (24h, 48h, and 72h) 
for the RenG2 cell line, determined by the MTT assay. The results are 
represented as percentages in relation to the obtained control values. In this 
graph is also represented some statistically differences between drug 
concentrations and between both drugs. All the cultures were prepared with 
an initial cell density of 8x10
3
cells/cm
2
. For each condition, the results are 
presented as the mean of three independent experiences (± standard 
deviation). *p<0.05, **p<0.01, 
#
p<0.001 
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As referred in Chapter 1, the term cancer refers to a broad category of diseases 
that arise as a result of the accumulation of mutations, chromosomal instability, and 
epigenetic events. Despite the fact that cancer is a common disease, the transition from a 
normal cell to a cancer cell is a very rare event, considering the number of cells making 
up an organism (Evan and Littlewood, 1998). This is mainly due to some fail-safe 
mechanisms within the cell that respond to DNA damage by either arresting cell cycle to 
allow DNA repair or to consent apoptosis (Argyle and Blacking, 2007). 
The discovery of CSCs in a number of human solid tumour types has suggested a 
central role in tumorigenesis due to their particular properties which include: self-renewal, 
which drives tumorigenesis and differentiation, contributing to cancer cell heterogeneity, 
their ability to seed new tumours and to spawn non-CSC populations lacking tumour 
initiating ability. There is also increasing evidence that these CSCs mediate tumour 
metastasis and, by virtue of their relative resistance to chemotherapy and radiation 
therapy may contribute to treatment resistance and relapse following therapy (Bonet and 
Dick, 1997; Clarke et al., 2006; Reya et al., 2001). Importantly, CSC-rich tumours are 
associated with aggressive disease and a poor prognosis (Ailles and Weissman, 2007), 
indicating that an understanding of their biology is pertinent to the development effective 
therapies. 
Both normal and neoplastic stem cells are thought to be self-renewing and to 
reside at the core of a cellular hierarchy, because through asymmetric division generate 
more differentiated progeny that lack self-renewal capacity (Alison and Islam, 2009; Tan, 
et al., 2006). Thus, intratumour heterogeneity may be explained by the ability of CSCs to 
generate neoplastic lineages at various differentiation stages even though, it is becoming 
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apparent that the differentiation states of the cells-of-origin can influence the organization 
of neoplastic cell populations (Ince et al., 2007; Lim et al., 2009). 
Recently, subsequent to the establishment of a tumorigenic cell line (RenG2) by 
exposure to Cr(VI), it were successfully implemented two different cell lines with 
increasing degree of malignancy, DRenG2 and DDRenG2, out of tumors induced in 
athymic nude mice by RenG2 and DRenG2 respectively. Unexpectedly, sub-populations 
with stem-like properties were present only in the more malignant DRenG2 and 
DDRenG2 cell lines evidencing that differentiated cell types can convert to stem-like 
cells and an unsuspected degree of cellular plasticity.  
In the present work, it was undertaken the study of the biology of the populations 
of RenG2 cells, obtained following prolonged treatment of differentiated non-tumorigenic 
bronchial epithelial cells (BEAS-2B) with Cr(VI), a known lung carcinogenic agent, and 
of DRenG2 and DDRenG2 cells, as well as, their precursor cell line BEAS-2B and the 
non-tumorigenic control of RenG2 cell line, Cont-1 cell line.  
 
4.1. Cytogenetic characterization of the DRenG2 and DDRenG2 cell lines   
Eukaryotic organisms have evolved robust mechanisms to ensure accurate 
segregation of the genetic material during mitosis. The cell cycle has checkpoints that 
delay chromosome segregation until DNA replication has been completed and the sister 
chromatids are properly aligned at the metaphase plate. However, these safeguards 
occasionally fail, resulting in unequal cell divisions that lead to developmental defects 
and cancer (Hardy and Zacharias, 2005).   
A hallmark of human cancers is genomic instability (Hanahan and Weinberg, 
2011). This instability can be represented as gains or losses of whole chromosomes or 
translocations/deletions/duplications of chromosomes’ segments (Fang, X and Zhang, 
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2011). This instability may lead to a state of polyploidy, if the chromosomal alteration is 
a linear multiplication of the entire set of the chromosomes, or it may lead to a state of 
aneuploidy, which refers loss or gain of single chromosomes or fragments (usually 
associated to a cancer phenotype) (Ganem, et al., 2007; Panigrahi and Pati, 2009). In 
most cases, the aneuploidy can be caused by mitotic errors due to defects in the 
mechanisms that have evolved to ensure faithful chromosome segregation (i.e. spindle 
assembly checkpoint) (Sheltzer and Amon, 2011). Other potential mechanisms that may 
be involved in chromosome segregation errors are the abnormal amplification of 
centrosomes, with its consequent abnormal chromosome separation, and abrogated 
cytokinesis (Jefford and Irminger-Finger, 2006; Jung et al., 2007). One of the 
consequences of this deregulation and of the consequent changes in the karyotype is the 
cellular transformation, a process that enhances the proliferative capacity of a cell, which 
often occurs in cancer cell lines (See section 3.3) (Sheltzer and Amon, 2011). Finally, 
another characteristic of aneuploid cells is that unlike DNA damage, once a cell becomes 
aneuploid, there is almost no way to correct the lost or the gained chromosomes, which 
implicates that the progeny will remain aneuploid (Rasnik, 2002).  
In the present work, aiming to observe the major cytogenetic events underlying 
the malignant transformation process and the appearance of CSCs sub-populations it was 
undertaken a cytogenetic study of these more malignant cell lines using conventional G-
banding and FISH study addressed to the chromosomes with apparent major alterations. 
As mentioned in chapter 3.1, the karyotype analysis of DRenG2 and DDRenG2 cell lines 
showed some structural alterations that have already been described for the BEAS-2B cell 
line (Rodrigues et al., 2009). However, they also revealed some structural alterations of 
their own, like the 7p
-
, and the loss of the Y chromosome, for both cell lines. And the 7q
-
, 
i9q
+
 for the DRenG2 cell line and t(7;14), 17q
+
 for the DDRenG2 cell line 
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The 7p region harbours genes for the EGFR (epidermal growth factor receptor) 
and for the IGF binding proteins 1 and 3 (IGFBP1 and IGFBP3) at 7p12-14 (Bergamo et 
al., 1999). This region was reported to be associated with metastatic tumors, while the 
gain in the 7p region was suggested to be linked with a non-metastatic tumor phenotype 
(Bergamo et al., 1999). 
Another recurrent chromosomal aberration is the loss of the Y chromosome, 
which is frequently reported in lung cancer (Luk et al., 2001; Berker-Karauzum et al., 
1998).  
The alterations that were characteristic of the DRenG2 were the 7q
-
 and iso9q
+
. 
This is the first time that these alterations were observed in cancer cell lines, since they 
haven´t been described in the recent literature yet. However, rearrangements on 
chromosome 9 are characteristic of some cancers, including gliomas, acute lymphoblastic 
leukemia, and certain forms of lung cancer and finally, in the bladder tumours (Coleman 
et al., 1994). A frequent chromosome rearrangement that has been detected in these types 
of cancer is the loss of heterozygosity (LOH) on chromosome 9, thus suggesting that loss 
of one or more suppressor gene(s) on chromosome 9 may be an early or initiating event in 
tumorigenesis (Coleman et al., 1994; Simoneau et al., 1999). Besides that, it is known 
that this chromosome harbours the tumour suppressor gene P16 (Berrieman et al., 2004). 
Finally, the gain of an isochromosome, such the ones that appear in this cell line (i5 and 
i9), has also been strongly associated with drug resistance (Selmecki et al., 2006).     
The translocation (7;14) observed in the line DDRenG2 has been also observed in 
patients with neurocysticercosis (NCC), which is associated with a high frequency of 
DNA damage in human circulating lymphocytes and with the development of 
haematological malignancies (Herrera et al., 2001). A feature of chronic NCC is a 
constant antigen stimulation, which may increase the frequency of aberrations of 
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chromosomes that harbour regions constantly rearranged during T and B lymphocyte 
maturation e.g., chromosomes 7 and 14  (Herrera et al., 2001). A common chromosome 
aberration that occurs between these chromosomes is the t(7;14) due to their 
hypermutation (Klein, 2000).   
The alterations mentioned before can be correlated with the enhanced drug 
resistance that was observed in the DRenG2 and DDRenG2 cell lines (See section 3.4) 
(Li et al., 2005). This is also confirmed in Duesberg paper (Duesberg et al., 2007), where 
he correlates the cancer cells karyotype with drug resistance, in other words, Duesberg 
and collaborators defends that when cancers cells acquire resistance against drugs, they 
acquire new karyorype alterations and/or they lose old ones (karyotypic theory).  
Finally, it is important to give emphasis, to the fact that aneuploidy is not a mere 
by product of tumorigenesis, but might be its cause (Boveri, 2008). For instance, during 
oncogenic transformation aneuploidy provides the precancerous cells the ability to evolve 
into more malignant state and to adapt to the “harsh” environment (Fang and Zhang, 
2011) due to the presence of extra genes. 
 
 
4.2. Characterization by immunocytochemistry of the BEAS-2B, Cont1, 
RenG2, DRenG2 and DDRenG2 cell lines 
To further understanding the biology of the cell lines, the next step was to evaluate 
their epithelial, mesenchymal or stem-like phenotype, and whether they express the P-
glycoprotein (efflux protein) liable for their increasing resistance to chemotherapeutic 
drugs. 
MNF116 is an anti-cytokeratin antibody that reacts with the Cytokeratins 5, 6, 8, 
17 and probably also 19 (Moll et al, 1982). This antibody shows an especially broad 
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reactivity pattern towards human epithelial tissues i.e., from simple glandular to stratified 
squamous epithelium, and can be used in the detection and classification of normal and 
neoplastic cells of epithelial origin. 
 As mentioned in section 3.2, all cell lines express MNF116, which was expected, 
since these cell lines have an epithelial origin. However, it was expected that, in the more 
malignant cell lines DRenG2 and DDRenG2, the level of MNF116 staining should be 
weaker since these cell lines would tend to an epithelial- or mesenchymal- transition 
phenotype (Kalluri and Weinberg, 2009). Instead, the DRenG2 and the DDRenG2 cell 
lines were the ones that showed the higher MNF 116 antibody staining.  
Vimentin is a type III intermediate filament protein normally expressed in cells of 
mesenchymal origin (Steinert and Roop, 1988). However, Vimentin expression has been 
described in epithelial cells involved in pathological or physiological processes which 
involve epithelial cell migration (Gilles et al., 1999).  
The malignant cell lines RenG2, DRenG2 and DDRenG2, showed a higher 
Vimentin staining when compared to the non-malignant cell lines BEAS-2B and Cont-1. 
The increase on the Vimentin staining level is correlated with malignancy, as Vimentin 
staining of DDRenG2 is the strongest, suggesting that these cells’ progress to a more 
malignant state involves an epithelial to mesenchymal transition (EMT), since Vimentin 
staining is characteristic of a mesenchymal phenotype (McInroy and Määttä, 2007).  
The hallmark of cancer malignancy is the metastatic dissemination of the primary 
tumours, which at the beginning are inept to invade the surrounding tissue. However, 
following the accumulation of genetic and/or epigenetic alterations and interactions with 
their environment, a small number of cells may bypass fundamental rules of the normal 
behaviour, detaching from the neighbouring ones, allowing the migration and metastases 
formation (Miller et al., 2005; Voulgari and Pintzas, 2009; Kong, et al., 2011). Increasing 
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evidence suggests that migrating cells involved in the process mentioned acquired an 
EMT phenotype (Mani et al., 2008; Kalluri and Weinberg, 2009), which may explain the 
observation that cancers with strong Vimentin expression have poor prognosis (Thomas 
et al., 1999).   
Oct3/4 is an essential transcriptional regulator of genes involved in maintaining 
the pluripotency and self-renewal of embryonic stem (ES) cells (Burdon, 2002) and may 
prevent the expression of genes activated during differentiation (Lee et al., 2010). Besides 
that, Oct3/4 plays a crucial role in maintaining cancer stem-like cell phenotype and the 
chemoresistance properties in cancers (Chen et al., 2008). Thus, it would be expected that 
the more malignant DRenG2 and DDRenG2 cell lines would stain positive for Oct3/4. 
Surprisingly, this wasn’t observed, possibly, because CSCs are a small subset of cells 
population, representing a very minor sub-population of the cells, and, thus, their 
identification by immunocytochemistry is very difficult.   
P-gp belongs to the ABC family transporters which usually are over-expressed in 
CSCs, leading to the MDR observed in current therapies (O’ Brien et al., 2009) (See 
section 4.4). So, it would be expected to have the expression of this protein in the 
DRenG2 and DDRenG2 cell lines. However, this antibody stained negative for all the cell 
lines, which leads to the conclusion that the observed drug resistance in these cell lines 
(See section 3.4) is due to other mechanism than the enhanced drug extrusion promoted 
by this protein (See section 4.4)  
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4.3. Duplication cell time of 5 cell lines (Beas-2B, Cont1, RenG2, DRenG2 
and DDRenG2)    
Normal tissues carefully control the production and release of growth-promoting 
signals that allows the cells to entry into and progress through the cell cycle, thereby 
ensuring the cell number homeostasis and consequently the maintenance of normal tissue 
architecture and function (Argyle and Khanna, 2006). However, in some cases there is 
deregulation of these signals, leading to an uncontrolled cell proliferation, which is 
maintained by growth-stimulating pathways (e.g. EGF, TGF-α and bFGF) activated, 
independently of their normal tissue environment, culminating in cancer (Moch et al., 
1997; Kuhn et al., 2003; Hanahan and Weinberg, 2011). On the other hand, CSCs, as well 
as normal SCs, are believed to be relatively quiescent (Signore et al., 2011). Although, 
the cell lines DRenG2 and DDRenG2 have a small subset of CSCs, surprisingly, they 
were the ones that showed a lower cell doubling time. Apparently, these cell lines may 
have gained alterations in essential genes that control cell death, cell differentiation 
and/or cell proliferation that increased their proliferation rate, a fundamental property of 
tumour cells (Sekine and Saijo, N., 2001; Panigrahi and Pati, 2009). In addition to the 
capability of inducing and sustaining cell proliferation through growth-stimulatory 
signals, cancer cells must also evade growth suppressors, which are powerful programs 
that negative regulate cell proliferation; many of these programs depend on the action of 
tumours suppressor genes, especially Rb and Tp53 proteins quite often involved in 
apoptotic cell death (Hanahan and Weinberg, 2011). In fact, a factor that may contribute 
to the malignant cells lower cell doubling time is the resistance cell death, quite common 
in cancer cells because, usually, these cells have the apoptotic genes mutated or mis-
regulated, and, consequently, the apoptotic pathways down-regulate (Panigrahi and Pati, 
2009).  
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DNA-damage signals activates the Tp53 gene that encodes the tumour suppressor 
p53, which then activates p21 expression to enforce cell cycle arrest, or activates Bax 
expression to enforce apoptosis, which leads to programmed cell death (PCD) (Koty et 
al., 1999).  PCD is a genetically regulated pathway that is altered in many cancers, and is 
regulated by the ratio of PCD inducers (Bax) or inhibitors (Bcl-2). And so, an abnormally 
high ratio of Bcl-2 to Bax prevents PCD (Koty et al., 1999). Type I PCD or apoptosis is 
critical for cellular self-destruction for a variety of processes, namely the prevention of 
oncogenic transformation (Hotchkiss et al., 2009). A mode of apoptotic cell death is the 
anoikis, which is trigger in consequential to insufficient cell-matrix interactions and is a 
critical player in tumour angiogenesis and metastasis, since tumour cells have the ability 
to survive in the absence of adhesion to the ECM (Rennebeck et al., 2005; Sakamoto and 
Kyprianou, 2010).  
The resisting cell death mechanisms mentioned before might largely explain the 
lower double cell time observed in the malignant cell lines, RenG2, DRenG2 and 
DDRenG2, in relation to the precursor cell line BEAS-2B, especially the possible absence 
of death by anoikis in the malignant cell lines, since they showed an altered morphology, 
to a more fibroblast cell-like (Figure 3.6), which is better suited to survive in absence of 
cell adhesion. So, tumour cells can escape from detachment-induced apoptosis by 
controlling anoikis pathways. 
 Other alternative forms of programmed cell death include autophagy and necrotic 
cell death (Portt et al., 2011).  
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4.4 Drug resistance/cell viability  
Existing therapeutic approaches have been largely based on the stochastic model, 
since most chemotherapeutic agents are addressed to the tumour major sub-populations 
which have a limited self-renewal and proliferative potential. Till know, these therapeutic 
approaches haven’t been successful, since most therapeutic effects are usually transient 
and fail to cure most cancers. 
The chemotherapy failure is due mainly to inadequate pharmacokinetic properties 
of the drug, tumour cell intrinsic factors such as the expression of drug efflux pumps and 
tumour cell extrinsic conditions present in the tumour microenvironment, i.e., hostile 
conditions as hypoxia, acidosis and nutrient starvation that render the well adapted cancer 
cells particularly resistant to cytotoxic drugs (Gatti and Zunino, 2005; Gottesman, 2002).    
In the present work cisplatin (cDDP) and gemcitabine (GEM), the most common 
anti-neoplastic agents used in lung cancer treatment were used to evaluate the 
chemoresistance of the cells lines. The cDDP was the first member of a class of platinum-
containing anticancer drugs, followed by carboplatin and oxaliplatin. The cDDP 
biochemistry mechanism of action is common to many other platinum agents and their 
most important biological target it’s the DNA (Lippard, 1982).  cDDP like many DNA 
damaging agents, acts as a cross-linker, inhibiting both DNA replication, and RNA 
transcription, and leading to cell cycle arrest and apoptosis (Rosell et al., 2002).      
GEM (2’2’-difluorodeoxycytidine), an analogue of cytosine arabinoside (ara-C), is 
a novel pyrimidine nucleoside antimetabolite (Huang et al., 1991). Unlike its analogue, 
GEM has demonstrated activity in a wide range of solid cancers, including the lung 
cancer (Lund et al., 1993). GEM exhibits cell-phase specificity, primarily killing cells 
undergoing DNA synthesis (S phase) and also blocking the progression of cells through 
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the G1/S-phase boundary, which leads to inhibition of DNA synthesis and cytotoxicity 
(Chiappori and Rocha-Lima, 2003).    
As depicted in the Figures 3.11-3.17 in chapter 3.4, the more malignant DDRenG2 
cell line presented the highest resistant to both drugs during the 3 days of exposure (24h, 
48h,72h), followed by DRenG2 cell line. The recent findings that both DRenG2 and 
DDRenG2 cell lines have sub-populations of cells with stem-like properties (Rodrigues et 
al., 2011)  explain the chemotherapeutic resistance to either cDDP and to GEM, and is in 
line with the observation that tumours that contain sub-population(s) of self-renewing and 
expanding stem cells known as CSCs, are highly resistance to the conventional 
chemotherapies.  
 The MDR promoted by CSCs is a serious problem in cancer chemotherapies, The 
CSCs resistance is mostly due to the over-expression of several energy-dependent drug 
efflux pumps, belonging to the ABC family of transporters, such as P-Glycoprotein and 
the MDR-associated proteins (MRPs), that are rightly described as guardians of the CSCs 
(Leitner et al., 2007; Chen et al., 2010). The over-expression of the ABC transporters 
occurs in response to drug exposure, being regulated genetically and epigenetically 
(Amiri-Kordestani et al., 2012). However, in our study none of the cell lines, including 
the chemoresistant DRenG2 and DDRenG2 express the P-Glycoprotein. Thus, resistance 
of DRenG2 and DDRenG2 to the DNA damaging agent cDDP may be due either to 
MRPs overexpression or to very efficient DNA damage repair systems. Unlikely DRenG2 
and DDRenG2, RenG2 is much less resistant to cDDP, although the genes that code for 
proteins involved on DNA repair, namely RAD51, XRCC3 and OGG1 [homologous 
recombination (HR)], XRCC1 [base excision repair (BER)], XRCC5 (NHEJ) and MLH1 
(MMR), are highly expressed (Rodrigues et al., 2009), as well as  hypoxia-inducible 
factor (HIF) which, in response to hypoxia, was reported to activate the multidrug 
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resistance 1 (MDR1) gene which encodes for the membrane- resident P-Glycoprotein 
responsible for drug extrusion ((Rohwer and Cramer, 2011;. Comerford et al., 2002),  
In the light of the observations, possible strategies for the successful eradication of 
CSCs, might be blocking EMT and targeting the self-renewal controlling pathways (Wnt, 
Notch and Hedgehog) (Signore et al., 2011; Alison et al., 2012; Gao et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
5. Concluding remarks 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Regardless the progress made in the cancer research field and the numerous 
theories that have emerged to explain its formation and progression, which have brought 
new and complementary points of view and new questions to be answered, this disease is 
still not fully understood.   
This study demonstrated that the DRenG2 and DDRenG2 cell lines, which have a 
subset of CSCs populations, despite their negative staining for the Oct3/4 antibody, had 
marked structural and numeric alterations in relation to their precursor BEAS-2B cells, 
which means that through their evolution since a non-malignant state to a malignant state 
they acquired genetic alterations that altered their phenotype. This was demonstrated by 
the strong staining observed for the Vimentin antibody in the DDRenG2 cell line. These 
phenotypic changes are the visualized consequences of their altered intrinsic 
characteristics, such as resisting cell death, evading growth suppressors, and sustaining 
proliferative signalling. These characteristics are emphasised by the resistance to cDDP 
and GEM of the malignant and proliferative DRenG2 and DDRenG2 cell lines, 
comparatively with the other cell lines, which supports the hypothesis that CSCs are 
responsible for the observed resistance to the conventional therapies.  
Between other things, the observed resistance in CSCs cell lines is usually due to 
the presence of a transport system-resistance to chemotherapy, P-gp. However, the 
DRenG2 and DDRenG2 cell lines stained negative for this antibody, which means that 
the drug resistance observed in these cell lines is correlated with other mechanism(s).  
This work confirms some point of views that have been developed through the last 
years in the cancer field, nevertheless, further work still needs to be done to unravel the 
formation of the CSCs and to develop better therapies that can improve the survival of the 
patients.     
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